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ABSTRACT 
 
TITLE:  A randomized clinical trial to evaluate the efficacy of Arimedadi oil pulling 
in plaque induced gingivitis, and its effect on metabolic marker in gingival crevicular 
fluid. 
BACKGROUND:  In the oral cavity, plaque forms biofilm/pellicle over the tooth 
surface, that harbours numerous microorganism. These microorganisms cause 
inflammation of the gingiva, which is termed as gingivitis. The changes noticed are 
red, swollen, spongy and bleeding gums. No studies till date have taken place to 
scientifically prove the efficacy of kabala (medicated oil pulling) in periodontal 
conditions. Arimedadi tailam, classical ayurvedic formulation is indicated in mukha 
rogas (diseases of face and oral cavity) in general and specific, oral conditions, danta 
vidradhi (alveolar abscess), seetada (spongy or bleeding gums), dantaharsha 
(odontitis), krimidanta (caries), dalana (tooth ache) and the like.        
AIM:   To evaluate the efficacy of Arimedadi oil pulling (which is a medicated oil 
containing Ayurvedic medicaments) in plaque induced gingivitis and to assess the 
clinical and biochemical changes that take place. The patients are randomly selected. 
Clinical and biochemical parameters are assessed at baseline, II week and IV week.  
MATERIALS AND METHODS: Twenty nine patients who were diagnosed with 
gingivitis were advised to practice Oil pulling therapy or Chlorhexidine rinsing or 
Placebo mouthrinsing containing mint flavored distilled water for a period of 30 days. 
The baseline and post-intervention (II week and  IV week) - Gingival Index, Plaque 
Index, Modified Sulcular Bleeding Index and GCF PGE2 levels were assessed to 
quantify the statistical difference between these two groups.   
RESULTS: Significant reduction was observed between the baseline and post-
intervention (II week and IV week) Gingival Index, Plaque Index, Bleeding scores 
and GCF PGE2 levels in the chlorhexidine group and Oil pulling group. However, this 
reduction was greater in Chlorhexidine group than oil pulling group. Overall from 
baseline to II week and IV week, when the reduction in PlI, GI, BOP and GCF PGE2 
values were compared for the CHX and Oil pulling groups, the difference was 
statistically significant (P=0).  
CONCLUSION: The anti-plaque and anti-gingivitis activity of CHX was superior to 
Arimedadi Taila, though there was significant reduction observed in both groups. 
Overall, from baseline to II week and IV week, when the reduction in PlI, GI, BOP 
and GCF PGE2 values were compared for the CHX and Oil pulling groups, the 
difference was statistically significant (P=0). In the Placebo group there was no anti-
plaque and anti-gingivitis activity, which was in contrast to CHX and Oil pulling 
group. The present study results showed that PGE2 levels in GCF were found to be 
more sensitive to changes in gingival inflammation. 
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 In humans, dental biofilms accumulate on a daily basis. The basic research 
during the last century has clearly established the role of dental plaque at the 
interfaces of tooth and gingiva as the main cause of gingival inflammation, which 
could lead eventually to periodontitis.  
 Gingivitis, the commonest of all periodontal diseases is the inflammation of 
gingiva; characterized by host tissue inflammation due to bacterial plaque 
accumulation. It may be characterized by the presence of any of the following clinical 
signs: redness and edema of the gingival tissue, bleeding upon provocation, changes 
in contour and consistency, presence of calculus and/or plaque, and no radiographic 
evidence of crestal bone loss.1 The conventional methods of controlling periodontal 
disease involve the mechanical removal of plaque & calculus. Maintenance of 
effective plaque control is the cornerstone of any attempt to prevent and control 
periodontal disease. However the quality of self performed mechanical plaque control 
is not sufficiently effective in most individuals and should be improved.2 
  Chemotherapeutic agents and antimicrobial agents are a common adjunct to 
mechanical hygiene measures to facilitate the control of supragingival plaque and 
gingivitis and its use has been known for decades. Mouth rinses represent one form of 
attack on oral microbes and malodor. The first reference to mouth rinsing around 
2700 B.C. is credited to Chinese medicine literature for treatment of diseases of the 
gums by rinsing with urine of a child. We have come a long way since then to the use 
of chlorhexidine (CHX) now for over three decades.3 
 The advent of chemotherapy, antiseptics and antimicrobial compounds 
eventually paved way for a variety of chemical formulations which possessed anti- 
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plaque activity. CHX is an antimicrobial agent and it deservedly has a place in the 
dental armory used to treat or prevent periodontal disease, and has earned its eponym 
of the gold standard against which other antiplaque and gingivitis agents are  
measured.4 
 Oil pulling, in CAM (Complementary and Alternative Medicine), is a 
procedure that involves swishing oil in the mouth for oral and systemic health 
benefits. It has been used extensively as a traditional Indian folk remedy for many 
years to prevent decay, oral malodor, bleeding gums, dryness of throat, cracked lips 
and for strengthening teeth and gums.5 Ayurvedic books like Sushruta Samhita, & 
Charaka Samhita have mentioned the importance of Arimedadi Taila in the 
management of dental diseases. Arimedadi Taila was proved to be effective in 
reducing periodontal problems like bad breath, bleeding gums and swollen gums 
along with sensitivity of teeth in more than 80% of patients.6   
 Periodontal diagnosis and treatment plan are based on the assessment of 
clinical parameters and radiographic findings. However, these clinical parameters are 
not sufficiently sensitive and specific to identify disease activity in individual sites or 
to predict future attachment loss. Hence attention is focused on the development of 
diagnostic tools that could screen and differentiate the active inflamed sites and 
predict future tissue destruction.7 
  Prostaglandin E2 (PGE2) is one of the most potent biochemical mediators of 
inflammation which plays an important role in the pathogenesis of periodontal 
diseases. PGE2 levels in gingival crevicular fluid (GCF) can serve as an indicator of 
the status of ongoing disease activity.8 
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 Despite the wealth of information published, there has been little data on the 
impact of plaque control measures on PGE2 levels and the role of PGE2 in the 
progression of gingivitis. Hence, this study was planned to comparatively evaluate the 
efficacy of Chlorhexidine rinses and oil pulling with Arimedadi Taila in preventing 
plaque formation and progression of gingivitis. This study was also planned to assess 
the changes in GCF PGE2 levels during health and gingivitis, and to assess the impact 
of plaque control measures on PGE2 levels. 
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Aim:  
 To assess the clinical and biochemical changes that take place after the use of 
arimedadi OP in plaque induced gingivitis.   
Objectives :   
• To evaluate the efficacy of Arimedadi Taila in controlling plaque induced 
gingivitis;  
• To compare the efficacies of CHX and Arimedadi Taila in preventing plaque 
formation and progression of gingivitis;  
• To evaluate the levels of PGE2 and its role in plaque induced gingivitis; 
• To assess the impact of plaque control measures on GCF PGE2 levels. 
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 GCF AND ITS ROLE IN PERIODONTAL HEALTH AND DISEASE:  
 Waerhaug J (1952)15 gave an early account of the presence of GCF in the 
‘gingival pockets’ and their possible role in disease and health. 
 While investigating the physiological properties of the gingival pocket, he 
administered India ink into healthy gingival sulci of young experimental dogs. After 
1hour, he observed increased fluid transudation and emigration of leukocytes and 
within the next 48 hours this ‘transudate fluid’ had eliminated most of the ink 
particles from the sulci. It was suggested, a flushing action of fluid originating from 
the gingival sulcus, which could aid in the removal of particulate matter from the 
sulcular space.  
 Brill and Krasse (1958)16 in his experimental study, passed filter paper strips 
into the gingival sulcus of dogs, who were injected with sodium fluorescein. He 
demonstrated that parenterally administered tracer material could be recovered on 
strips of filter paper. However, no dye was detected on other intraoral locations, such 
as the teeth, tongue, palate, oral mucosa, and even extra-oral mucous membrane sites. 
These findings suggested that the epithelial lining of the gingival sulcus was 
permeable to small molecular weight compounds and that the passage of tissue fluid 
into the sulcus acts as a possible defense mechanism.16,17 
 Edelberg J (1966)18 investigated the histology of the vasculature underlying 
the sulcular and junctional epithelium. A suspension of carbon particles was injected 
intravenously into the dogs, which were later sacrified and their gingival tissue was 
examined. The authors found that carbon particles remain in the capillaries and 
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venules concluding that the production of GCF is primarily related to an increase in 
permeability of the vessels underlying the junctional and sulcular epithelium.  
 Bang and Cimasoni (1971)19 utilized the Folin phenol protein quantitation 
method (proposed by Lowry et al 1951) to detect the total protein concentration of 
GCF and serum in 20 patients. They found that there was no significant difference 
between the protein concentrations in serum and GCF and thus concluded that GCF 
was an inflammatory exudate that passes the crevicular barrier, as a result of increased 
capillary permeability.19 GCF flow changes can be monitored to detect subclinical 
inflammation, followed by analysis of chemical and microbial constituents for 
differentiating active and quiescent lesions.20 
 Alfano et al (1976)21, through their human study postulated that proteinaceous 
substances increase GCF flow initially by establishing an osmotic gradient 
(transudative) and later by initiating inflammatory changes (exudative changes). In 
this study, baseline GCF samples were taken for one min. from the midlabial surface 
of two similar teeth from 12 healthy men. In the control teeth, phosphate buffered 
saline was introduced into the gingival sulcus while on the experimental teeth, an 
identical volume of phosphate buffered saline, modified to contain 10 mg/ml of 
homologous human serum albumin, was introduced. The flow rate was 84% higher on 
the experimental site at 3 hours and more than 100% higher at 6 hours compared to 
baseline levels. A hypothesis was put forth that in healthy gingiva a small amount of 
subgingival plaque gives rise to limited quantities of macromolecule by-products 
which will be removed by being absorbed to the surface of desquamating epithelial 
cells or through phagocytosis. When more molecules are present, they diffuse 
intercellularly to the basement membrane which can be considered as a major limiting 
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barrier. As the macromolecules accumulate at the basement membrane, an osmotic 
gradient is created and the GCF is produced. GCF flow changes can be monitored to 
detect subclinical inflammation, followed by analysis of chemical and microbial 
constituents for differentiating active and quiescent lesions.21  
 Pashley DH (1976)22 developed a mathematical model based upon the starling 
factors governing fluid distribution across capillaries and the authors found that GCF 
production is modulated by capillary filtration and lymphatic uptake. From this, they 
concluded that when the production of fluid from capillaries is greater than the 
lymphatic uptake, it will accumulate as edema fluid or leave the area as GCF. GCF 
flow changes can be monitored to detect subclinical inflammation, followed by 
analysis of chemical and microbial constituents for differentiating active and 
quiescent lesions. 
 Curtis et al (1988)23 estimated the total protein concentration by repetitive 
sampling for GCF over a 10 minute period. The mean concentration of the first 
sample was comparable to that of normal tissue fluids and lymph, irrespective of the 
state of inflammation of the sample site. However, during repeated sampling, the 
values rose to resemble serum protein levels, except at those sites with no clinically 
detectable inflammation. These findings are consistent with the hypothesis that, in 
health GCF represents the transudate of gingival tissue interstitial fluid but in the 
course of gingivitis and periodontitis, GCF is transformed into true inflammatory 
exudate.  
 Darany et al (1992)24 measured the GCF flow rates and elastase activity in 56 
patients at different levels of gingival inflammation. They found GCF flow rate to be 
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more sensitive to early inflammatory changes leading to mild gingivitis, than GCF 
elastase activity.     
 Lamster and Novak (1992)25 reviewed the literature pertaining to the 
contents of GCF and stated that GCF contains bio-markers which reflect the 
microbial, inflammatory and metabolic activities within the gingival 
sulcus/periodontal pocket. GCF flow changes can be monitored to detect subclinical 
inflammation, followed by analysis of chemical and microbial constituents for 
differentiating active and quiescent lesions.  
 
Fig.1. Biomarkers in GCF 
 
 
 
REVIEW OF LITERATURE 
 
  9 
GCF COLLECTION METHODS  
 Brill and Krasse et al (1958)16 recorded the occurrence of fluorescein in 
gingival pockets by means of filter paper strips. The strips were used in two different 
ways. In the intracrevicular method, the end was gently inserted into the pocket, 
whereas for the extracrevicular method the strips were placed on the vestibular 
surface of teeth, marginal and attached gingiva. Weinstein et al (1967) inserted 
preweighed twisted thread in to the gingival crevice around the tooth and determined 
the amount of fluid collected by weighing the sample.
26
 
 Griffiths GS (2003)12 classified methods of GCF collection using filter strips, 
depending upon the placement, into intracrevicular technique, where the strips are 
placed at the entrance (Fig.2b) or base of the crevice/pocket (Fig.2c) and 
extracrevicular techniques, where the strips are overlaid on the gingival crevice region 
(Fig.2a).  
 The micropipette method of GCF collection is ideal as it provides an undiluted 
sample of ‘native’ GCF whose volume can be accurately assessed. There is less 
chances of any proteins or cells getting entangled during the collection process or 
retrieval, but it is difficult to collect an adequate volume of GCF in a short period, 
unless the sites are inflamed and contain large volumes of GCF.  
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Fig. 2. Different levels of placement of filter strips a) Extracrevicular method b) 
Intracrevicular method (superficial) c) Intracrevicular method (deep)  
 
Micro-capillary tubes or micropipettes:  
 Sueda et al (1969)27 in a quantitative analytic study, stated that GCF from 
the crevice migrates into the tube by capillary action and because the internal 
diameter is known, the volume of fluid collected can be accurately determined by 
measuring the distance to which the GCF has migrated. 
Fig. 3. Collection of GCF using micropipettes 
 
 
REVIEW OF LITERATURE 
 
  11 
Gingival washings method:  
 Oppenheim FG (1970)28 modified gingival washing technique, which 
involved the construction of a customized acrylic stent, isolating the gingival tissues 
from the rest of the mouth. The tissues were then irrigated for 15 min, with a saline 
solution, using a peristaltic pump and the diluted GCF was removed. The production 
of customized acrylic stents is complicated and technically demanding especially in 
the mandibular arch, because of the difficulties in producing a technically satisfactory 
appliance for the mandibular arch. It is also a disadvantage that GCF from individual 
sites cannot be analyzed. GCF flow changes can be monitored to detect subclinical 
inflammation, followed by analysis of chemical and microbial constituents for 
differentiating active and quiescent lesions. 
 Skapski & Lehner (1976)29 introduced a crevicular washing method, in 
which the gingival crevice was perfused with an isotonic solution Hank’s balanced 
salt solution. Instillation and re-aspiration of 10 ml of Hank’s balanced salt solution at 
the interdental papilla was carried out. This process was repeated 12 times to allow 
thorough mixing of the transport solution and GCF. The fluid collected represented a 
dilution of crevicular fluid and contained both cells and soluble constituents such as 
plasma proteins. This technique could therefore be applied either to individual 
interdental units or to multiple units which were then pooled. 
 Bickel et al (1984)30 inserted a periopaper strip (developed by Harco 
electronics Ltd) between the two jaws of periotron, which produces the flow of 
electric current and gives a digital read out on the screen. The volume of the fluid 
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collected on the filter paper strips was measured. Translation of Periotron values to 
clinical conditions and GI with which they are associated are given below Tab.112 
Tab. 1. Translation of Periotron values to clinical conditions and GI 
 
 Koregol et al (2011)31 performed a clinico-biochemical study to estimate 
sodium, potassium and calcium concentrations of GCF in gingivitis and periodontitis 
to find the reliability of these ions as diagnostic markers and to analyze the relation of 
these ions to one another. This would indicate the stage of disease activity, which 
inturn helps in early diagnosis, prevention and treatment of periodontal diseases. The 
patients selected for the study included both sexes, aging from 18 to 55 years, divided 
into 2 groups: gingivitis (group I) and periodontitis (group II).  
 Using volumetric microcapillary pipette, 5 μl GCF was collected for 
quantitative analysis of sodium, potassium and calcium using flame photometry. The 
concentrations of sodium, potassium and calcium in GCF and their significant 
correlation with GI and pocket depth measurements, reflect the clinical status of 
gingival and periodontal tissues. In conclusion, estimation of these electrolytes may 
be used as potential diagnostic markers of active disease status in periodontal tissues 
and to predict the effective methods for prevention and treatment. 
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 Guentsch et al (2011)32 carried out a clinical study to compare three different 
sampling techniques to determine, whether one method yielded samples suitable for 
the reproducible and simultaneous determination of bacterial load, cytokines, 
neutrophil elastase and arginine-specific gingipains. GCF was sampled from four sites 
per patient (one sample per quadrant using two samples per method) in 36 patients 
with chronic periodontitis. One week later, the procedure was repeated with 
alternative methods.  
 Variables determined were, loads of Aggregatibacter actinomycetemcomitans 
and Porphyromonas gingivalis, levels of IL-6 and -8, activity of neutrophil elastase 
and level of arginine-specific gingipais. The detected cytokine levels were higher 
using paper strips compared to paper points. Bacterial loads found in paper strips and 
paper points were similar. Arginine-specific gingipains were only detectable in high 
quantities by washing the periodontal pocket. The level of arginine-specific 
gingipains correlated with the load of Porphyromonas gingivalis.   
 In conclusion, they stated that use of paper strips was suitable for the 
simultaneous determination of microbial and immunologic parameters. Obtaining 
GCF by washing can be useful for special purposes. The gingipain concentration in 
periodontal pockets was directly determined to be ≤1.5μM. This value indicated that 
most of the substrates of these proteases identified until now can be easily degraded in 
Porphyromonas gingivalis-infected sites.  
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ROLE OF CHX MOUTHRINSES IN REDUCING GINGIVAL 
INFLAMMATION:   
 At physiological pH, CHX is a strong base and dicationic at PH levels above 
3.5 with two positive charges on either side of a hexamethylene bridge. It is 
chemically (1,6-di(4-chlorophenyl-diguanido) hexane.33 
Fig. 4. Structure of CHX molecule 
 
Mechanism of action: Antibacterial activity :  
 CHX has a wide spectrum of activity encompassing gram-positive and gram-
negative bacteria, yeasts, dermatophytes and some lipophilic viruses. Its antimicrobial 
activity is of the membrane-active type, used to describe an antimicrobial agent that 
damages the inner (cytoplasmic) membrane. CHX shows different effects at different 
concentrations; at low concentrations the agent is bacteriostatic, whereas at higher 
concentrations the agent is rapidly bactericidal. The actual levels at which the 
bacteriostatic and bactericidal effects manifest themselves vary between bacterial 
species.4  
 The antibacterial mode of action of CHX is considered to be as follows: the 
bacterial cell is characteristically negatively charged and the cationic CHX molecule 
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is rapidly attracted to the negatively charged bacterial cell surface, with specific and 
strong adsorption to phosphate-containing compounds. This alters the integrity of the 
bacterial cell membrane. CHX is attracted towards the inner cell membrane and binds 
to phospholipids in the inner membrane, leading to increased permeability of the inner 
membrane and leakage of low-molecular-weight components, such as potassium 
ions.4  
 At this bacteriostatic (sublethal) stage, the effects of CHX are reversible. 
Increasing the concentration of CHX causes progressively greater damage to the 
membrane, leakage of low-molecular weight cytoplasmic components falls, reflecting 
the coagulation and precipitation of the cytoplasm by the formation of phosphate 
complexes such as adenosine triphosphate and nucleic acids.4 
 Chawner and Gilbert (1989)34 performed a comparative study of the 
bacteriostatic and bactericidal activities of alexidine and chlorhexidine. They 
suggested that there may either be specific binding sites for these molecules in the 
bacterial membrane or different intramolecular interactions of the two molecules at 
the membrane, the differences in the endgroup substitution between the biguanides 
affect their ability to produce lipid domains in the cell membrane. 
Antiplaque effects:  
 Davies (1973)35 considered that sucrose enhancement plaque formation may 
reduce the effects of CHX, such that the low “bacteriostatic” levels of CHX are no 
longer able to penetrate the cell wall of plaque bacteria grown in the presence of 
excess sucrose. At physiological pH, CHX is a large dicationic molecule, which has 
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the ability to adsorb onto negatively charged surfaces, such as bacterial cell walls, 
where it exerts its bacteriostatic and bactericidal effects. 
 Addy M (1986),36 in a review, ascribed CHX’s antiplaque activity to its 
property of substantivity, which is the ability of an antimicrobial agent to persist 
within the oral cavity. He conducted an experimental study in a group of volunteers to 
compare the effects of a 0.2% CHX gluconate mouthrinse and a 0.035% Alexidine 
mouthrinse on plaque accumulation and salivary bacteria.  
 The subjects refrained from all forms of oral hygiene during the 10-day 
periods and rinsed twice a day with the mouthwash randomly allocated to the 
respective period. They found that after a single rinse with CHX, the saliva itself 
exhibits antibacterial activity for up to 5 hours.  
  CHX, also binds to the different surfaces within the mouth (teeth and mucosa) 
and also to the pellicle and saliva; for example, after a single rinse with CHX, the 
saliva itself exhibits antibacterial activity for up to 5 hours,37 whereas persistence at 
the oral surfaces has been shown to suppress salivary bacterial counts for over 12 
hours.38 
 Although CHX is able to bind to different anionically charged elements within 
the oral cavity, it also maintains its antibacterial activity for several hours.37 Given 
that plaque formation occurs on the tooth surface, the binding of CHX to the pellicle-
covered tooth surface was considered to be small compared with that involved in 
CHX-protein interactions at other oral surfaces.35  
 Jones CG (1997)4 postulated that CHX, desorbed from the oral mucosa, might 
have three mechanisms of plaque inhibition: an influence on pellicle formation by 
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blocking the acidic groups on the salivary glycoproteins, thus reducing the protein 
adsorption to the tooth surface; an influence on the adsorption of plaque onto the tooth 
surface by binding to the bacterial surface in sublethal amounts and an influence on 
the formation of plaque by precipitating the agglutination factors in saliva and 
displacing calcium from the plaque matrix.  
 For CHX to exert an antiplaque effect it must first be delivered successfully, in 
an active form, onto the tooth surface. On rinsing with CHX, there is an immediate 
reduction in the salivary bacterial counts. This reduction persists for several hours 
because of the substantivity of CHX, both within the saliva, and from mucosally 
desorbed CHX into the saliva.4  
 However, this is irrelevant to the inhibition of plaque by CHX. At the clean 
tooth surface a small amount of CHX binds to the pellicle and enamel, where it 
remains for several hours. This tooth surface-bound CHX can then interfere with the 
adherence of bacteria to the tooth surface through several mechanisms.4 
 Hjeljord et al (1973)39 found that, in vitro reactions of CHX with soluble and 
precipitated proteins were reversible, with CHX, binding more strongly to precipitated 
proteins than to soluble proteins. The authors hypothesized that the CHX-protein 
interaction could involve a slight denaturation of the protein adsorbed to the teeth, and 
the slow reversibility of this reaction could partly explain the retention and slow 
release of CHX in the oral cavity.  Similar effects seen with the more usual 10ml, 
0.2% solution (20mg) can also be achieved with high volumes of low concentration 
solutions, as reported by Lang et al (1981).40 
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 Jenkins et al (1988)41 by topically applying 0.2% solutions of CHX only to 
the tooth surface, including by the use of sprays, reported the same level of plaque 
inhibition as rinsing with the full 20 mg dose  & it showed that plaque growth on 
enamel inserts was inhibited equally well by 0.2% CHX applied topically or by 
rinsing.  They observed enamel inserts under electron microscope and concluded that 
CHX achieved its antiplaque effect as a result of an immediate bactericidal action at 
the time of application, followed by a prolonged bacteriostatic action as a result of 
CHX adsorbing to the pellicle-coated enamel surface. This implied that the tooth 
surface-bound CHX was of greater importance in preventing plaque formation.  
 Jenkins et al (1994)42 comparatively evaluated different doses of CHX for 
their anti-plaque activity against 0.1% triclosan. They found that even 0.01% CHX 
mouthrinse also had better anti-plaque efficacy which was superior to 0.1% triclosan 
rinse and considerable plaque inhibition was obtained with doses as low as 1-5mg 
twice daily. Their results revealed that anti-plaque effect of CHX was dose related  
Efficacy of CHX mouthrinses:   
 Loe & Schiott (1970)43 in an experimental human study, evaluated the effect 
of mouthrinses and topical CHX on the development of dental plaque and gingivitis, 
the authors concluded that rinsing with 10 ml of 0.2% w/v CHX gluconate 
mouthwash for 1 min, twice daily completely prevented the formation of plaque and 
gingivitis, provided the agent is administered in such a way that it reaches all tooth 
surfaces. Once rinsing with CHX was terminated, plaque formed again. 
 Cumming & Loe (1973)44 showed that plaque control could also be achieved 
by lowering the concentration of CHX, whilst increasing the volume of the solution. 
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They concluded that the optimal dosage of CHX was 400 ml of a 0.025% to 0.05% 
solution as an oral irrigator and 50 ml volume of a 0.075% to 0.1% when used as a 
mouthwash. 
 Lang et al (1981)40 compared several different regimens using mouthwashes 
with different concentrations and concluded that regular and daily use of 0.1% or 
0.2% CHX mouthwash significantly reduced the development of plaque and 
gingivitis.  
 Brecx et al (1989)45 showed that three daily rinses with 0.12% CHX 
gluconate matched the effect of optimally performed mechanical oral hygiene 
techniques. CHX has been studied in a number of controlled clinical trials. Tab. 2. In 
these studies, plaque reduction has ranged from 16-66% and gingivitis reduction has 
ranged from 24-80%.   
Tab. 2. Clinical trials associated with the use of CHX mouthwash 
Study Trial  
length 
(months) 
Concentration 
of CHX  
Plaque 
reduction  
(%) 
Gingivitis 
reduction  
(%) 
Flotra et al (1972)46 4 0.2% 66 24 
Lang et al (1982)47 6 
0.1% 
0.2% 
16 
19 
67 
80 
Grossman et al (1989)48 6 0.12% 49 31 
Loe et al (1976) 49 24 0.2% 45 27 
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Toxicology, safety and side effects:  
 Flotra et al (1972)46 in their 4-month study conducted to evaluate the effect of 
CHX mouthwash on 50 soldiers, summarized the side effects of CHX mouthrinse as 
follows -  
1. Brown discoloration of the teeth, some restorative materials and of the dorsum 
of the tongue.  
2. Taste perturbation, where the salt taste appears to be preferentially affected and 
leaves food and drinks with a bland taste.  
3. Oral mucosal erosion which appears as an idiosyncratic reaction and 
concentration dependent. Dilution of the 0.2% formulation to 0.1%, but 
rinsing with the whole volume to maintain dose, usually alleviates the 
problem. Erosions are rarely seen with 0.12% rinse products used at 15 ml 
volume.  
4. Unilateral or bilateral parotid swelling is an extremely rare occurrence and the 
reason for the same has not been identified. However, recent reports have 
attributed parotid gland swellings as a consequence of the rinsing action and 
not to the contents within mouthrinses.  
5. Enhanced supragingival calculus formation which may be due to the 
precipitation of salivary proteins on to the tooth surface, thereby increasing 
pellicle thickness and/or precipitation of inorganic salts on to the pellicle layer. 
Bacterial resistance or evidence of super-infection by fungi, yeasts or viruses 
has not been reported with long-term oral use. 
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 The phenomenon of surface adsorption appears fundamental to the antiplaque 
activity of the cationic antiseptics. Moreover, reaction with chromogenic material is 
relevant to the local side effect of staining.  
 Moran et al (1984)50 performed a study inorder to determine, how such local 
reactions affect the antibacterial activity of some of these antiseptics. The minimum 
inhibitory concentration of commercial mouthrinses containing alexidine, cetyl 
pyridinium chloride, CHX gluconate and hexetidine against Oxford staphylococcus 
(National Collection of Type Culture - NCTC 6571) and Escherichia coli (NCTC 
10418) was established by tube dilution.  
 The minimum inhibitory concentration of polymethylmethacrylate polymer on 
and of tea on Oxford staphylococcus was then measured. The zones of inhibition 
around acrylic blocks soaked in the respective antiseptics, with and without post 
exposure washings, were measured. The effects of tea on zone width of the antiseptic 
soaked blocks were recorded. The minimum inhibitory concentration values of 
alexidine, cetyl pyridinium chloride and CHX gluconate, but not hexetidine, were all 
increased by adding polymethylmethacrylate to cultures. Tea added to the culture 
increased the minimum inhibitory concentration values against E. coli for alexidine, 
CHX and hexetidine. 
 Zones of inhibition around antiseptic-treated blocks were reduced by washing 
and, in the case of hexetidine, completely abolished. Tea-soaking further reduced the 
zones of inhibition for alexidine and CHX, but not cetyl pyridinium chloride. It was 
concluded that surface adsorption and/or reaction with chromogenic material reduces 
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the antibacterial activity of the cationic antiseptics. Hexetidine in the mouthrinse 
employed appeared to possess little or no adsorption potential to acrylic. 
 Baker et al (1987)51 in an invitro study, assessed the antimicrobial effect of 
CHX and other compounds formed by replacement of side chains of CHX. The 
authors found that CHX acts by generalized perturbation of the bacterial membrane 
rather than in the antibiotic mode (lack of activity against specific bacterial enzymes 
or receptors), which decreased the chances for development of bacterial resistance. 
 Quirynen et al (2000)52 conducted a clinical study was performed to examine 
the relative importance of the use of CHX in the one stage full-mouth disinfection 
protocol. Three groups of 12 patients each with advanced periodontitis were followed, 
both from a clinical and microbiological point of view, over a period of 8 months. The 
patients from the control group were scaled and root planed, quadrant per quadrant, at 
two-week intervals. The 2 other groups underwent a one stage full-mouth scaling and 
root planing (SRP) (all pockets within 24 hours) with full-mouth disinfection using 
CHX or without full-mouth scaling and root planing and the adjunctive use of CHX. 
At baseline and after 1, 2, 4 and 8 months, the following clinical parameters were 
recorded: PlI, GI, Probing depth (PD), BOP and clinical attachment level. 
Microbiological samples were taken from different intra- oral niches (tongue, mucosa, 
saliva and pooled samples from single- and multirooted teeth). The samples were 
cultured on selective and non-selective media in order to evaluate the number of 
colony-forming units/ml for the key-periodontopathogens. 
 All 3 treatment strategies resulted in significant improvements in all clinical 
parameters, but the full-mouth disinfection and full-mouth SRP patients reacted 
always significantly more favourably than the control group, with an additional PD 
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reduction of 1.5 mm and an additional gain in attachment of 2 mm (for pockets >7 
mm). Also from a microbiological point of view both the full mouth SRP and full 
mouth disinfection patients showed additional improvements when compared to the 
control group. The differences between full-mouth SRP and full-mouth disinfection 
patients were negligible. In conclusion, these findings suggest that the benefits of a 
‘‘one-stage full-mouth disinfection’’ in the treatment of patients suffering from severe 
adult periodontitis. 
 Sekino et al (2003)53 carried out a double-blind crossover clinical trial to 
study the effect of different CHX regimens on the number of bacteria in saliva, and on 
de novo plaque formation. Ten subjects with gingivitis, but no signs of destructive 
periodontitis, were recruited. Following a screening examination, the volunteers were 
given oral hygiene instruction, meticulous scaling and professional mechanical tooth 
cleaning. The professional mechanical tooth cleaning was repeated once every 3 days 
during a 2-week period to establish healthy gingival conditions. This includeed three 
phases. Each experimental phase comprised one preparatory period of 7 days and one 
plaque accumulation period (no oral hygiene measures) of 4 days.  
 During all preparatory periods, the volunteers (i) performed mechanical tooth 
cleaning using a toothbrush and dentifrice and (ii) were, in addition, given two 
sessions of professional mechanical tooth cleaning. The final professional mechanical 
tooth cleaning was delivered after bacterial sampling had been made on Day 0. In the 
preparatory period A, the participants continued the self performed plaque control 
regimen that employed only mechanical means. In the preparatory period B, the 
participants were in addition instructed to rinse and gargle, twice daily, with a 0.2% 
CHX mouthrinse. In the preparatory period C, in addition to the above, the 
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participants were instructed to brush the dorsum of the tongue for 60 secs, twice daily, 
with a 1.0% CHX gel. Following each plaque accumulation period, there was a 10-
day washout interval. The presence and amount of dental plaque Quigley-Hein plaque 
index (QHI) was scored after 1, 2 and 4 days of no oral hygiene.  
 Samples of saliva were obtained on Day 0 and after 1 and 2 days. The samples 
were placed on Brucella agar plates and incubated (anaerobically) for 5 days. The 
total number of colony-forming units was determined and used to estimate the density 
of bacteria in saliva. In period A, the mean QHI increased from 1.0 (Day 1) to 1.4 
(Day 2) and 2.1 (Day 4). The corresponding scores for periods split B and C were 0.5, 
0.8, 1.6 and 0.3, 0.8, 1.2, respectively. At all re-examination intervals more plaque 
formed during period A than during periods B and C. Further, during period C, less 
plaque formed than that during period B. Saliva samples from Day 0 in period A, 
contained a larger number of total viable counts than the baseline samples in periods 
B and C. There was no significant difference in total viable counts among the groups 
on Day 2. In conclusion, the daily use of CHX as an adjunct to mechanical tooth 
cleaning markedly reduced the number of microorganisms that could be detected in 
saliva. 
 Karpinski et al (2003)54 performed a systematic review of pharmaco-
biological activity and application of CHX and showed that it has strong biocidal 
activity against Gram-positive bacteria and weaker activity against Gram-negative 
bacteria. It is also active against yeasts, some dermatophytes and some lipophilic 
viruses. Numerous studies have confirmed the beneficial effects of CHX in reducing 
plaque accumulation, tooth caries, gingivitis, periodontitis and in alveolar osteitis. 
Unfortunately, CHX exhibits cytotoxic activity on human cells, can cause colorization 
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of teeth and fillings and its activity depends on the pH of the environment and the 
presence of organic substances. In conclusion, CHX plays a valuable role in the 
dentistry and antisepsis. However, it can also cause side effects, limiting its 
application time.   
 Sharma et al (2009)55 reported a case report of an immediate hypersensitivity 
reaction (urticaria) to CHX due to oral rinsing of CHX gluconate mouthwash (Rexidin 
mouthwash). The prevalence of contact urticaria and anaphylaxis due to CHX remains 
to be unknown. The adverse reaction was confirmed by skin prick test.  After 
thorough oral examination of a 19-year-old female patient with the chief complaint of 
bleeding from the gums, she was advised oral prophylaxis and was prescribed CHX 
mouth rinse (Rexidin), twice daily for a period of three weeks.  
 Next day, patient presented with urticaria on her forehead and face, the front 
of the elbows and forearms, side and upper back region of the neck and on the lower 
abdomen. No oral changes were observed. On questioning, the patient reported using 
CHX mouthwash (Rexidin) formulation in a 1:1 concentration and rinsed with it for at 
least 1 min. On rinsing with it for the first time she noticed reddening on her forehead, 
face and side of the neck (after about 12 hour of using it). On waking up the next 
morning, she felt some burning sensation on the red spots, which she had noticed the 
previous night. Upon using the formulation again, after a couple of hours she 
observed marked redness on her upper back, neck region, lower abdomen, and on the 
front of the elbow and forearms. This was accompanied with irritation. History of any 
previous such allergic reactions were also recorded. To confirm that the allergic 
reaction was due to CHX, skin prick test was performed as follows: The inner forearm 
of the patient was cleaned with soap and water and was coded with a skin marker pen. 
  25 
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A drop of allergen (CHX) was then placed besides the mark. A small prick through 
the drop was made to the skin using a sterile prick lancet.  
 The excess allergen solution was dabbed off with a tissue. The skin under the 
drop of the CHX solution had become red and itchy within 30 min and this was 
surrounded by a white raised wheal. Hypersensitivity and other adverse reactions to 
CHX are rare, but its potential to cause anaphylactic shock is probably 
underestimated. In conclusion, CHX is the most effective and widely used antiplaque 
agent to date. Nevertheless, the present case report would remind the clinicians of an 
important potential risk of this widely used antiseptic and make them cautious before 
prescribing any CHX formulation as it may lead to local symptoms or even severe 
attacks. 
 Berchier et al (2010)56 conducted a systematic review to evaluate the effects 
of 0.12% CHX mouthrinse compared with 0.2% on plaque and periodontal 
parameters. Plaque scores, parameters of periodontal inflammation and periodontal 
attachment loss were selected as primary outcome parameters. Screening of 409 titles 
and abstracts, eight eligible publications were identified. A meta-analysis of seven 
studies using the same PlI showed a significant difference between 0.2% and 0.12% 
CHX (p=0.008). Three studies that compared 0.12% and 0.2% CHX mouthrinse 
products showed no difference in the effect of gingivitis between the two 
concentrations.   
 In comparing 0.12% and 0.2% CHX, information concerning the effect on 
gingival inflammation was sparse and no studies could be found that compared the 
two CHX concentrations and evaluated the probing pocket depth and/or the 
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periodontal attachment level. With respect to plaque inhibition, the results showed a 
small but significant difference in favour of the 0.2% CHX concentration. However, 
the clinical relevance of this difference is probably negligible.  
 Van Maanen-Schakel et al (2012)57 carried out a systematic review, to search 
the literature concerning the inhibiting effect of an oxygenating agent on CHX 
induced tooth staining. Controlled / andomized controlled clinical trials conducted 
with healthy subjects > 16 years of age that compared the effects of CHX mouthrinse 
combined with an oxygenating agent with the effects of CHX alone were included.  
Combining an oxygenating agent with CHX mouthrinses led to a significant reduction 
in tooth staining, when compared with CHX alone. One of the included studies 
reported a side effect for one participant. Limited availability of data, and the included 
studies were methodologically and clinically heterogeneous, which affected the 
quality and interpretation of the evidence. In conclusion, there is moderate evidence 
that a combination of CHX and an oxygenating agent reduces tooth staining without 
interfering with plaque growth inhibition. 
 Pedrazzi et al (2014)58  reviewed the importance of antimicrobial mouthrinse 
use as an auxiliary method in chemical peri-implant biofilm control. The active 
ingredients of the several available mouthrinses include bis-biguanide, essential oils, 
phenols, quaternary ammonium compounds, oxygenating compounds, chlorine 
derivatives, plant extracts, fluorides, antibiotics and antimicrobial agent combinations. 
It was concluded that there is strong clinical evidence that at least two mouthrinses 
have scientifically proven efficacy against different oral biofilms, i.e., CHX 
digluconate and essential oils; however, 0.12% CHX digluconate presents a number 
of unwanted side effects and should be prescribed with caution. Chemical agents 
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seem beneficial in controlling peri-implant inflammation, although they require 
further investigation. A scientifically proven antiseptic, with significant short and long 
term efficacy and with no unwanted side effects, for the prevention and/or treatment 
of peri-implant disease was recommended. 
 Slot et al (2014)59  performed a systematic review about the efficacy of CHX 
and tooth discoloration. Based on the existing scientific literature, the effect of CHX 
dentifrice/gel as compared to a regular or placebo dentifrice/gel is established in 
healthy adults on the primary outcome parameters of plaque and gingivitis scores. 
Tooth surface discoloration was evaluated as a side effect. Randomized controlled 
clinical trials, regarding self-performed brushing by adults without periodontitis, with 
a minimum duration of 4 weeks were included. Regarding plaque score reduction, the 
majority of the experiments using a CHX dentifrice provided a significant positive 
effect.  
 All studies assessing gingival bleeding as parameter for gingivitis observed a 
significant reduction in favour of CHX dentifrice over PL dentifrice. Tooth surface 
discoloration was more pronounced with CHX dentifrice. The combined data 
concerning parameters of interest for CHX gel compared with a placebo did not show 
a trend towards a beneficial effect on plaque and bleeding scores.  
 In conclusion, within the limitations of this analysis, it may be concluded that 
toothbrushing with a CHX gel does not provide conclusive evidence. Brushing with a 
CHX dentifrice can be effective with regard to the control of plaque and gingivitis. 
Tooth surface discoloration was observed as side effect, which can potentially have a 
negative impact on patients’ compliance. 
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 Jose et al (2015)60 carried out a randomized, examiner-blinded, parallel-group 
study to assess gingival bleeding following twice-daily use of 0.2% w/v CHX 
digluconate mouthrinse with and without alcohol (0.2% CHX-alcohol; 0.2% CHX-
alcohol-free, respectively) and brushing with a standard fluoride toothpaste was 
compared to brushing alone. Three hundred and nineteen subjects with mild-to-
moderate gingivitis were included. A prophylaxis was performed at baseline. Gingival 
Severity Index (GSI; primary objective), GI and PlI were assessed at baseline and 
after 6 weeks of treatment. Adverse events were recorded throughout the study.  
 Between treatment, differences at week VI, demonstrated significantly lower 
Gingival Severity Index for the 0.2% CHX-alcohol and 0.2% CHX-alcohol-free 
groups compared to brushing alone. There were also significant reductions in GI and 
PI for the 0.2% CHX-alcohol and 0.2% CHX-alcohol-free groups compared to 
brushing alone. The proportion of subjects reporting ≥1 treatment-related adverse 
events was 27.8% (0.2% CHX-alcohol), 24.8% (0.2% CHX-alcohol-free) and 3.7% 
(brushing alone).  
 In conclusion, CHX mouthrinse with or without alcohol, as an adjunct to 
brushing with regular fluoride toothpaste significantly reduces bleeding scores, plaque 
and gingival inflammation compared to brushing alone. Treatment-related adverse 
events are characteristic of those associated with the use of CHX and are similar for 
both mouthrinses. 
  Marrelli et al (2015)61 carried out a clinical study to test the anti 
discoloration system (Curaden Healthcare) in comparison with the other mouthwashes 
without this system. Antiplaque activity showed by 3 of the most commercialized 
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mouthwashes was tested, moreover, their ability in reducing the dental staining 
related to the oral use of CHX was also assessed.  
 The results demonstrated the clinical efficacy of the 3 mouthwashes, when 
compared with CHX. The anti discoloration system performed particularly well, with 
a clinical detection of dental staining significantly less than the others tested. This 
study demonstrated the clinical efficacy of anti discoloration system in the reduction 
of tooth staining, without a loss of antiplaque activity with respect to the competing 
mouthwashes containing CHX.  
HERBAL MOUTHRINSES AND THEIR ROLE IN GINGIVAL AND 
PERIODONTAL DISEASES:    
 OP is an age-old process mentioned in Charaka Samhita and Sushrutha’s 
Arthashastra. The process is called Kavala Gandoosha/kavala Graha in Ayurveda. 
This process is said to cure about 30 systemic diseases.62 It has been used extensively as 
a traditional Indian folk remedy for many years to prevent decay, oral malodor, 
bleeding gums, and dryness of throat, and cracked lips and for strengthening teeth, 
gums, and jaws.63 Panchakarma ayurvedic therapy which is a distinctive method of 
detoxifying the body offers great hope in future for development of strategies targeted 
towards prevention of gingival and periodontal diseases.63 
 Gandusha and Kavala Graha are two primary oral cleansing techniques; 
specialized therapy to treat as well as to prevent oral diseases. In Gandusha, the oral 
cavity is filled completely with liquid medicine, held for about 3-5 min or until nasal 
discharge or lacrimation occured and then released. 
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  In Kavala Graha, the mouth is filled with a comfortable or three-quarters 
amount of fluid and is retained with the mouth closed for about 3 min. and then 
gargled. These oral cleansing techniques can benefit bad breath, dry face, dull senses, 
exhaustion, anorexia, loss of taste, impaired vision, sore throat and all kapha related 
imbalances.5  
 Other advantages of OP over commercially available chemical preparations 
include- it does not cause staining of teeth or allergic reactions and it does not leave 
behind a lingering taste.14  
 Abraham et al (2005)65 performed a comparative study to evaluate the 
inhibitory activity of Triphala mouthrinse on Polymorphonuclear neutrophil-type 
MMP-9, in adult periodontitis patients.Tissue extracts from 10 periodontitis patients 
were treated with Triphala, doxycycline and kamillosan. The inhibition was analyzed 
by gelatin zymography, and the percentage of inhibition was determined by a gel 
documentation system. Comparison of type of mouthrinse used and its percentage 
inhibition of MMP activity is given in Tab. 2.   
Tab. 3. Comparison of type of mouthrinsing & its inhibition of MMP-9               
activity (%) 
    Type of mouthrinse Reduction of  
MMP-9 activity (%) 
Triphala 76.6% 
Kamillosan (1,500 µg/ml) 46.36% 
Doxycycline (300 µg/ml) 58.7% 
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 Yun et al (2007)66 investigated the inhibitory effect of (-)-epigallocatechin 
gallate, the main constituent of green tea polyphenols, on survival of osteoclasts, 
differentiated from Cells of the murine monocyte/macrophage cell line, Raw 264.7 
cells. The effect of (-)-epigallocatechin gallate on osteoclast survival was examined 
by tartrate-resistant acid phosphatase staining in osteoclasts differentiated from RAW 
264.7 cells. 
  Involvement of caspase in (-)-epigallocatechin gallate-mediated osteoclast 
apoptosis was evaluated by treatment with a general caspase inhibitor, Z-VAD-FMK, 
using a DNA-fragmentation assay.  
 Moreover, the effect of (-)-epigallocatechin gallate on the activation of 
caspase-3 was assessed by a colorimetric activity assay and western blotting. (-)-
Epigallocatechin gallate significantly inhibited, in a dose-dependent manner, the 
survival of osteoclasts differentiated from RAW 264.7 cells and induced the apoptosis 
of osteoclasts.  
 Treatment with (-)-epigallocatechin gallate resulted in DNA fragmentation and 
induced the activation of caspase-3 in RAW 264.7 cell-derived osteoclasts. Additional 
treatment with Z-VAD-FMK suppressed these effects of (-)-epigallocatechin gallate.  
 In conclusion, it was suggested that (-)-epigallocatechin gallate might prevent 
alveolar bone resorption by inhibiting osteoclast survival through the caspase-
mediated apoptosis. They suppressed the formation of osteoclasts by inhibiting the 
expression of matrix metalloproteinase-9 (MMP-9) in osteoblasts. 
  Asokan et al (2008)67 evaluated the effect of sesame OP on the count of 
Streptococcus mutans in plaque and saliva of children and found that it provided 
significant reduction in Streptococcus mutans count.  
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 Asokan et al (2008) 68 performed a comparative study to evaluate the effect of 
sesame OP and CHX rinses on plaque-induced gingivitis. They found statistically 
significant reduction of plaque and modified GI scores and a considerable reduction in 
the total colony count of aerobic microorganisms in both the groups. 
 Asokan et al (2008)67 through a series of in vitro studies, assessed the possible 
anti-plaque action of OP therapy and they concluded that emulsification of sesame oil 
and a saponification process, evidenced by increased consumption of sodium 
hydroxide may play vital roles in the anti-plaque activity. 
 
 
In a literature review of traditional therapies, the authors quoted references 
from ‘Charaka Samhitha,’ an ancient ayurvedic text about the use of a herbal 
preparation called Arimedadi Taila in the management of periodontal diseases.69 The 
contents of a conventional Arimedadi Taila6 have been listed in Tab. 4.   
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Tab. 4. Arimedadi Tailam Ingredients:  
Paste prepared with 12 grams of each of fine powders of,                 
 Yashti – licorice- Glycyrhizaglabra 
 Trijatha- cinnamon, cardamom and           
cinnamomumtamala 
 Manjishta – rubiacordifolia 
 Gayatri – acacia catechu 
 Lodhra – symplocosracemosa 
 Katphala – myricanagi 
 Kshirivrikshatwak 
 Irimedatwak-acacia 
leucophloea/farnesiana 
 Musta – cyperusrotundus 
 Agaru – aquilariaagallocha 
 Shvetachandana – santalum album 
 Raktachandana–terocarpussantalinus 
 Karpoora,camphor–   
cinnamomumcamphora 
 Jati – myristicafragrans 
 Takkola – illiciumverum 
 Mamsi – nardostachysjatamansi 
 Dhataki – woodfordiafruticosa 
 Gairika – red ochre 
 Mrinala – cymbopogonjwarancusa 
 Mishi – anethumsowa 
 Vaidedi- piper longum 
 Padmakesara – nelumbonucifera 
 Kumkuma – crocussativus 
 
 
 Laksha – lacciferlacca 
 Samanga, manjishta – rubiacordifolia 
 Brihati – solanumindicum 
 Bilvapatra – aeglemarmelos 
 Suradruma – cedrusdeodara 
 Shaileya – asphaltum 
 Sarala – pinusroxburghi 
 Sprikka – frlphiniumzalil 
 Palasha – buteamonosperma 
 Rajani – turmeric – curcuma longa 
 Daruharidra – berberisaristata 
 Priyangu – callicarpamacrophylla 
 Tejani – clematis triloba 
 Pradhakaleya – cosciniumfenestratum 
 Pushkara – inularaceomsa 
 Jaya – butilontheophrasti 
 Vyaghri – solanum xanthocarpum 
 Madana – randiadumetorum 
 Tila tila – sesame oil 
sesamuminidicum 
Decoction 
Arimeda- acacia leucophloea 
Nyagrodha-fiscusbengalensis 
Udumbara-fiscus racemosa 
Ashwattha-fiscus religiosa 
Plaksha-fiscus lacor 
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 Likewise, the extracts of neem, guava and miswak have been used as 
dentifrices, chewing sticks, gels and mouthwashes69 and mouth washes prepared from 
extracts of neem, guava, miswak, pomegranate, propolis, tulsi, craneberry and 
grapes70 have also been shown to improve clinical parameters in patients with 
gingival diseases. However, researches pertaining to the biochemical, microbial and 
molecular effects of herbal products are still lacking and further studies are needed in 
order to better understand the potential benefit of these products. 
 Hosokawa et al (2010)71 conducted an in vitro study about the catechin and 
found that it suppressed IL-6, C-C chemokine ligand 20 and CXC chemokine ligand 
10 production in stimulated gingival fibroblasts. In an another in vitro study, Tamura 
et al (2011)72 showed that catechins present in green tea derivatives can inhibit the 
growth of actinomyces, many periodontopathogens and oral candida species. This 
inhibition was hypothesized to be related to the generation of hydrogen peroxide, as 
the inhibitory effect was suppressed in the presence of catalase enzymes.  
 Dani et al (2015)73 performed a clinico-microbiological study in forty patients 
with plaque induced gingivitis. The patients were treated with SRP with ultrasonic 
instrumentation, following this randomly, twenty patients performed OP (sesame oil) 
procedure for 14 days, another twenty patients used CHX mouthwash for 14 days. At 
baseline all subjects were instructed to wash their mouth with physiological saline 
(0.85% NaCl).This saline was collected in a sterile container and was serially diluted 
and plated in Mueller Hinton Agar plates.      
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 The plates were incubated aerobically at 37˙C for 48hrs. After this incubation 
period the number of colonies present in 1ml of the saline was calculated by the 
formulae:  
 Number of bacteria/ml = Number of colonies dilution x Amount plated 
 OP with sesame oil, showed a greater reduction in the PlI scores by 51.6%, GI 
scores by 53.37% and total colony counts of aerobic microorganisms by 44.5% at 14 
days, as opposed to 47.61%, 44.58% and 41.3% for the same in CHX group.  
Studies on comparison of efficacy of CHX and Herbal mouth rinse:  
 Singh et al (2001)5 conducted a single blind parallel randomized controlled 
trial in 48 volunteers involving four groups. The subjects were refrained from all oral 
hygiene measures for 4 days, but rinsed instead twice daily with 10 ml of a herbal 
mouthwash, essential oil, CHX or a PL solution. PlI and plaque area was assessed on 
day 4. The herbal mouthwash and essential oil showed a significant inhibition of 
plaque regrowth compared to PL (P<0.001), but the lowest values of PI and plaque 
area were obtained with CHX. 
 Statistically significant difference in plaque parameters was observed when 
CHX was compared to herbal mouthwash and essential oil, and herbal mouthwash to 
essential oil rinse. In conclusion, the new herbal mouthrinse had a promising plaque 
inhibitory potential, but it is not as efficacious as CHX in preventing plaque regrowth. 
 Bajaj et al (2011)74  conducted a study in a total of 1431 students in the age 
group 8–12 years, belonging to classes fourth to seventh. The knowledge, attitude and 
practice of the subjects was determined using a questionnaire. The students were 
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divided into three groups namely, Group I (n = 457) using Triphala mouthwash 
(0.6%), Group II (n = 440) using CHX mouthwash (0.1%) and Group III (n = 412) 
using distilled water. The assessment was carried out on the basis of plaque scores, 
gingival scores, and the microbiological analysis (Streptococcus and lactobacilli 
counts).  
 Both the Group I and Group II showed progressive decrease in plaque scores 
from baseline to the end of 9 months; however, for Group III increase in plaque scores 
from the baseline to the end of 9 months was noted. Both Group I and Group II 
showed similar effect on gingival health. There was inhibitory effect on microbial 
counts except Lactobacillus where Triphala had shown better results than CHX. It 
was concluded that there was no significant difference between the Triphala and the 
CHX mouthwash.  
 Shetty et al (2013)75 conducted a study in 40 systemically healthy, chronic 
gingivitis subjects between the age groups of 18-25 yrs. The subjects received oral 
prophylaxis as part of phase 1 therapy after which they were asked to refrain from 
oral hygiene measures, and then randomly divided into 2 groups of 20 patients each, 
one prescribed CHX and the other, herbal mouthrinse (hiora) twice daily for 2 min. 
for four days. On day 5, subgingival plaque samples were collected for culture.  
 Clinical periodontal parameters viz PlI, GI and oral hygiene index were 
assessed on day 0 and day 5 and analyzed statistically.  There were no statistically 
significant differences between the two groups with regard to the clinical parameters 
and colony counts of the bacteria. However, the CHX group showed statistically 
suggestive significance with respect to inhibition of Streptococcus mutans (p<0.1) and 
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moderate significance with respect to inhibition of Aggregatibacter 
actinomycetemcomitans (p<0.05).  
 In conclusion, herbal mouth rinses may be as effective as CHX as chemical 
anti-plaque agents with fewer side effects. However, alternative study designs using 
larger sample sizes and longer duration are needed to further reiterate its benefits. 
 Naiktari et al (2014)76 conducted a double-blind, randomized, multicenter 
clinical trial in 120 hospitalized patients showing clinical signs of gingival 
inflammation who were equally divided into three groups. Patients in group A were 
advised to rinse their mouths with 10 mL of distilled water, group B with 0.2% CHX, 
and group C with Triphala mouthwash for 1 min twice daily for two weeks.  
 The PlI and the GI were recorded on the first and the fifteenth day. There was 
no significant difference when the efficacy of Triphala was compared with 0.2% 
CHX. However, a statistically significant difference was observed in PI and GI when 
both group B and group C were compared with group A and also within groups B and 
C, with no statistically significant difference between groups B and C after 15 days 
(P<0.05). When group B was compared to group C, there was no statistically 
significant difference (P˃0.05).  
 In conclusion, the Triphala mouthwash is an effective antiplaque agent like 
0.2% CHX in reducing plaque accumulation and gingival inflammation. It is also cost 
effective, easily available, and well tolerable with no reported side effects.  
 Lakade et al (2014)77 carried out a randomized controlled double-blind study 
to compare the antimicrobial efficacy of 0.2% CHX mouth rinse and mouth rinse 
containing 0.03% triclosan, 0.05% sodium fluoride, and 5% xylitol in reducing the 
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Streptococcus mutans count in plaque. Thirty healthy children aged 8-10 years with 
dmft (decay component) of three or four were selected.  
 They were divided randomly into two groups: The control or CHX group and 
the study group or combination mouth rinse. Both the groups practiced rinsing with 
respective mouth wash for 1 min. for 15 days, twice daily. The plaque samples were 
collected and after incubation Mutans streptococcus count was estimated on the strips 
from the Dentocult SM kit and evaluated using manufacture's chart. Statistically 
significant reduction in the Mutans streptococci count in the plaque was seen in the 
control and study group from baseline level. But when both the groups were 
compared, the antimicrobial effect of CHX was more. 
  Gupta et al (2015)78 conducted a double-blind randomized control trial 
among ninety undergraduate volunteer students. The students were randomly 
allocated into three study groups: 1) Terminalia chebula mouthwash, 2) CHX, 3) 
distilled water.  
 Assessment was carried out according to plaque score and gingival score. 
Results showed that Terminalia chebula mouthrinse is as effective as CHX in 
reducing dental plaque and gingival Inflammation. The results demonstrated a 
significant reduction of gingival bleeding and plaque indices in both groups over a 
period of 15 and 30 days as compared to the placebo. The authors concluded that 
Terminalia chebula extract mouthrinse can be used as an alternative to CHX 
mouthrinse as it has similar properties without the side-effects of the latter.  
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PGE AND ITS ROLE:    
 PGs are small-molecule derivatives of arachidonic acid (AA), produced by 
COXs (COX; constitutively active COX1 and inducible COX2 that convert AA into 
PGH2, and PGE synthases, with a relatively minor contribution of the isoprostane 
pathway. Local levels of PGE2 are regulated by the local balance between the COX2-
driven synthesis and 15-hydroxyPGE dehydrogenase (15-PGDH)-mediated 
degradation of PGE2. PGE2 is one of the most abundant PGs produced in the body. It 
can be produced by all cell types of the body, with epithelia, fibroblasts, and 
infiltrating inflammatory cells representing the major sources of PGE2 in the course of 
an immune response.  
Fig.  5. Pathways of PGE2 synthesis from arachidonic acid79 
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Receptors for PGE2 : 
 The receptors for PGE2 (EP1–EP4) are present on multiple cell types, 
reflecting the ubiquitous functions of PGE2, which span nociception and other aspects 
of neuronal signaling, hematopoiesis, regulation of blood flow, renal filtration and 
blood pressure, regulation of mucosal integrity, vascular permeability, and smooth 
muscle function.80  
 EP4 and to a lesser extent EP2 receptors were involved in the inhibition of 
TNF-a production. PGE2 suppresses production of chemokines including IL-8, 
monocyte chemoattractant protein-1, and macrophage inflammatory protein-1 via EP4 
receptors in human macrophages stimulated with lipopolysaccharide.81,82 
Role in inflammation:  
 In inflammation, PGE2 is of particular interest because it is involved in all 
processes leading to the classic signs of inflammation. Redness and edema result from 
increased blood flow into the inflamed tissue through PGE2 - mediated augmentation 
of arterial dilatation and increased microvascular permeability.83  These effects are 
enhanced by synergism with other inflammatory mediators.84,85  
 It also possess anti-inflammatory properties, the development and regression 
of inflammation probably depends partly upon relative concentrations of pro- and 
anti-inflammatory PG activity and possibly also on a feedback inhibition by PGS.79 
Role in immunity:    
 PGE2 supports acute local inflammation and phagocyte-mediated immunity at 
the site of pathogen entry, but it has a specialized role in controlling the potentially 
harmful activation of type 1 (cytotoxic) immunity, especially at later stages of 
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immune responses. Dysregulated PGE2 synthesis or degradation has been associated 
with a wide range of pathological conditions.81 Although this ability of PGE2 to limit 
type 1 immunity is crucial for the host self-preservation, it is counterproductive 
during infections with intracellular organisms, which both depend on enhanced PGE2 
production and/or on reduced degradation of PGE2 for the establishment of 
immunosuppression and disease progression.  
 Although the therapeutic antagonism with the PGE2 system has traditionally 
focused on the inhibition of PGE2 production using non selective or COX2-selective 
blockers, the newly available agonists and antagonists of the individual PGE2 
receptors, allow for new therapeutic approaches to control the PGE2-mediated 
immunopathology. Additionally, amplification of PGE2 production and 
responsiveness to this factor and antagonizing its rate of decay may be used to treat 
autoimmune phenomena.80  
    Offenbacher et al (1984)86 demonstrated that the concentration of PGE2 in 
GCF correlates with the concentration of PGE2 in the adjacent tissues and this was 
related to the existing attachment loss and it was approximately three times higher in 
GCF samples from patients with juvenile periodontitis compared to those with adult 
periodontitis. Subsequently, Offenbacher et al (1986)87 studied patients with adult 
periodontitis to determine the longitudinal relationship between the concentration of 
PGE2 in GCF and clinical attachment loss. 
  While increasing levels are seen from health to gingivitis to periodontitis,88 
healthy sites in patients with periodontitis experience also have higher levels of PGE, 
although levels are lower in maintenance patients than in patients with ongoing 
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periodontitis reported by Ebersole et al (1993).89 Thus individual site levels of PGE 
are difficult to reconcile with the clinical appearance of the site in isolation. 
  Offenbacher et al (1993)90 found that the amount of PGE2 released from 
stimulated cells of the monocyte/macrophage lineage (MØ) may have a genetic 
component. The association between MØ inflammatory mediator responses and 
Human leukocyte antigen (HLA) - haplotypes has profound implications in chronic 
inflammatory and autoimmune states. Patients having a high inflammatory response 
to LPS belonged to the HLA-DR4+ haplotype and the hyporesponsive subjects had 
HLA-DR2+ haplotype. This hyperresponsiveness due to HLA-DR4+ which has been 
found to be prevalent in diseases such as Rhematoid arthritis, Lupus Erythematosis 
and Diabetes mellitus could be the cause for susceptibility to severe and rapidly 
progressive forms of periodontitis. 
 PGE2 is an inflammatory mediator and is found to be elevated in inflamed 
gingival tissue and GCF proportional to the severity of periodontal disease.91,92 This 
was confirmed in a model of experimental gingivitis, where GCF PGE2 levels 
increased at 4 weeks following cessation of oral hygiene procedures.93 It was also 
suggested that what-ever the patient’s phenotype (i.e., disease resistant or disease 
susceptible), there is a natural tendency for PGE2 levels to gradually increase over 
time.94 
 Downie et al (1974)95 conducted a clinical study to measure the levels of PGE 
in the human endometrium throughout the normal menstrual cycle, which were 
measured by bioassay. PGE2 was found to be low during the proliferative phase of the 
cycle (10-25 ng/100 mg tissue). It remained lower during the luteal phase and was 
highest at menstruation (52ng / 100mg tissue). There is a cyclic variation in the levels 
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of PGE in the endometrium. The physiological significance of these changes remains 
to be elucidated.    
 Mendieta et al (1984)96 conducted a human study in 13 samples of inflamed 
human gingival tissue and 6 samples of normal human gingival tissue incubated with 
[l4C] arachidonate, PG metabolites were separated by thin-layer chromatography and 
identified by comparison with co-chromatographed standards. Inflamed gingival 
tissue synthesized, significantly larger amounts of 6-keto-PGF, thromboxane B2, 
PGD2 and PGA2 compared to normal tissue. Some unidentified metabolites, possibly 
lipoxygenase products, were detected in significantly larger amounts in inflamed than 
in normal tissue.  
 Ohm et al (1984)92 conducted a clinical study in 50 gingival biopsies taken 
from 50 participants (aged 22 to 56 years), undergoing periodontal surgery. All 
patients were subjected to a presurgical treatment including oral hygiene instructions, 
repeated plaque control, and removal of dental calculus. None of the patients was 
undergoing medical treatment.  
 The classification into gingivitis and periodontitis was made by the aid of the 
Periodontal Index of Russell (1956). The index has a scale of values which increases 
from 0 to 8 with increasing prevalence and severity of disease. Values of 1 and 2 
comprise the "gingivitis-group" and values from 6 to 8 comprise the "periodontitis-
group."  
 Gingivitis was diagnosed by inflamed gingival with formation of 
supraalveolar pockets exceeding 2 mm without any reduction of the height of the 
alveolar bone crest. Surgical treatment of gingivitis was carried out by gingivectomy 
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with an external bevel incision. Periodontitis was treated by flap surgery starting with 
a reversed bevel incision, so that the removed tissue was taken from the pocket and 
the gingival margin. Normal human gingival tissue was obtained during operative 
removal of impacted third molars. Clinical criteria for healthy gingival tissue were the 
absence of anomalous redness, no BOP, and a pocket depth not exceeding 2 mm distal 
of the second molar. Special attention was given to the fact that the third molar has 
had no connection to the oral cavity, so that there were no places for bacterial plaque 
to hide under a hood of inflamed mucosa behind the second molar. All biopsies were 
immediately frozen at -20°C in 0.9% sodium chloride solution.  
 The tissue samples of wet weight from 48 to 488 mg were homogenized and 
extracted twice with 6 ml of diethyl ether and once with 6 ml of ethyl acetate. 
Recovery values were about 95% after extraction.  
 The organic phase was evaporated to dryness under a stream of nitrogen at 
room temperature and the residue was redissolved in 200/µl of ethanol. Reversed 
phase High performance liquid chromatography (HPLC) was performed on a µ  
Bondapak "fatty acid analysis" column with the solvent system water:acetonitrile 
74:26 v/v, pH 3.1, running at a flow-rate of 0.6 ml/min. The recovery values of the 
chromatographic step varied between 82 and 95%.  
 Quantitative analysis of each fraction was performed by radioimmunoassay 
(RIA) using commercially available antibodies. PGEs considered were shown to 
increase during advancing periodontal destruction. The most quantitatively significant 
endoperoxide metabolites at every stage of inflammation were TxB2 and 6-keto-
PGF1α, followed by PGE2, 13,14Dihydro,15-Keto-PGE2, PGE1, PGF1α, PGF2α, and 
13,14Dihydro,15-Keto -PGF2α in decreasing order.   
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 Alexander et al (1996)97 carried out a clinical study to monitor IgGs, IL-lß, 
and PGE2 in GCF of 18 adult patients, as they progressed through periodontal 
treatment toward maintenance therapy. Sites were selected from the most severely 
affected sextant as determined by PD at initial examination. GCF was collected on 
four occasions: initial examination; 4 weeks after completion of initial therapy (oral 
hygiene counseling, and SRP); 3 months after completion of surgery; and 7 to 9 
months later at a maintenance visit. Significant improvements were observed for all 
the clinical variables measured: PD, attachment level, and BOP.  
 However, significant reductions for the GCF components only occurred in the 
concentrations of IL-1ß and PGE2, but were not evident until the maintenance 
sampling. Surprisingly, GCF:serum ratios of IgG subclasses did not change 
significantly over the course of the investigation. The robustness of the levels of these 
components may be due to inflammation associated with the healing process, or to a 
further plaque induced response. 96 
 Noguchi et al (1999)98 carried out an experimental study to investigate the 
involvement of COX-1 and COX-2 in PGE, production by periodontal ligament 
(PDL) cells stimulated with a proinflammatory cytokine, IL -1α (IL -1 α), and to 
examine the regulation of PGE2 production by cell-cell interaction of human gingival 
keratinocytes and PDL cells. It was found that IL-1α-stimulated PDL cells produced 
PGE2 in a time-dependent manner.  
 Indomethacin, a non-selective COX-1/COX-2 inhibitor, and NS-398, a 
selective COX-2 inhibitor, completely inhibited PGE2 production by the IL-1α -
stimulated cells. COX-2 mRNA was detected after IL-1α stimulation, although it was 
not detected in unstimulated cells. There was no difference in expression of COX-1 
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mRNA between unstimulated cells and IL-lα stimulated cells. Expression of COX-2 
protein in IL-1α -stimulated cells was increased, compared with that in unstimulated 
cells, whereas COX-1 protein expression was almost the same in both the cells.  
 Treatment of IL-1α -stimulated PDL cells with dexamethasone, known to 
inhibit COX-2 expression, prevented PGE2 production and COX-2 mRNA 
expression. Addition of the culture media of human gingival keratinocytes to PDL 
cells increased PGE2 production.  
 The PGE2 production was depressed by treatment of the cells with IL-1 
receptor antagonist and anti- IL-1α antibody, not with anti-IL-1β antibody. The PGE2 
production was also inhibited by treatment with NS-398 and dexamethasone. In 
conclusion, PDL cells stimulated with IL-1 α produce PGE2 through de novo 
synthesis of  COX-2 and that the cell interaction of gingival keratinocytes and PDL 
cells controls COX-2 expression and PGE2 Production via IL-1 α or a IL-1 α-like 
factor. 
   Morton et al (2001)99 conducted a research study in 32 gingival biopsies, 
obtained and processed histologically using hematoxylin and eosin, to determine the 
degree of inflammation. Of these biopsies, 7 with low and 7 with high histological 
levels of inflammation were further processed immunohistochemically in order to 
assess the levels of COX-2 expression in situ. To explore some potential mechanisms 
of COX-2 upregulation, gingival connective tissue primary cell cultures were 
established and challenged with periodontal bacteria or proinflammatory cytokines in 
vitro.  
 The levels of COX-2 expression were analyzed by western blot of cell lysates. 
COX-2 activity was assessed by quantifying PGE2 levels in culture supernatants by 
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competitive ELISA. The authors conclude that COX-2 expression is significantly 
upregulated in inflamed periodontal tissues. Both inflammatory cytokines such as IL-
1β and bacterial constituents may be responsible for the enhanced COX-2 expression 
and PGE2 synthesis in vivo.100  
 Rausch-Fan et al (2005)100 performed a clinical study performed to 
investigate the influence of glycine on PGE2 production. Human gingival fibroblasts 
were cultured in the presence of various concentrations of glycine and/or IL-1β, TNF-
α, and IL-10 and their influence on PGE2 production was measured. The expression of 
COX was analyzed by Western blot and immunocytochemistry.  
 The PGE2 production by IL-1β-stimulated human gingival fibroblasts was 
significantly upregulated by glycine. The effect of glycine on IL- 1β-induced cell 
proliferation and PGE2 production was concentration- dependent, reached a peak at 3 
mM, and declined slowly at higher doses.  
 The synthesis of PGE2 by human gingival fibroblasts cultured in the absence 
of glycine was significantly inhibited by IL-10 and partially induced in cells cultured 
with glycine. Glycine had no effect on TNF-α-induced PGE2 production. The IL-1β-
driven PGE2 synthesis was blocked by indomethacin, a COX-1/COX-2 inhibitor, and 
by COX-2 inhibitor NS-398.  
 The expression of COX-2 protein was slightly induced by glycine, more 
evidently by IL-1β, and mostly enhanced by combined IL-1β with glycine. Since 
PGE2 is a potent stimulator of bone resorption, and production of PGE2 and COX-2 
protein is augmented by glycine, our results strongly suggest that glycine may be 
involved in the pathogenesis of periodontitis. 
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 Siegel et al (2007)101 conducted a clinical study in 14 periodontally healthy 
subjects, who were divided into young (18–30 years, n=77) and elderly (46–77 years, 
n=7). A gingival biopsy was taken at baseline. After experimental gingivitis, clinical 
examination was repeated and a sec. biopsy was taken. The expression of COX-1, 
COX-2, COX3 and microsomal PGE synthase-1 was analyzed by means of 
immunohistochemistry. In both healthy age groups, COX-1 and microsomal PGE 
synthase-1 were expressed in epithelial cells, endothelial cells and fibroblast-like 
connective tissue cells.  
 COX-1 was found in Langerhans’ cells of the epithelium. COX-2 expression 
was observed in cells exhibiting the morphology of epithelial mitosis cells, and the 
expression of COX-2 in periodontally healthy elderly subjects was significantly lower 
(p ≤0.05). Following experimental gingivitis, COX-1 and microsomal PGE synthase-1 
expression did not change.  
 However, the expression of COX-2 was significantly increased in both age 
groups (p≤ 0.05). COX-3 was not detected in any group investigated. In conclusion, 
COX-1 and microsomal PGE synthase-I were found to be expressed constitutively in 
gingival tissue, and expression was unaffected by age or inflammation states. In 
contrast, the expression of COX-2 was weaker in elderly subjects. In the course of 
experimental gingivitis, COX-2 was induced in both age groups. 
 Becerik et al (2010)102 conducted a study in 25 gingivitis patients and 25 
periodontally healthy subjects having regular menstrual cycles were included and 
observed at menstrual phase (1 to 2 days of), ovulation phase (12 to 14 days), and 
premenstrual phases (22 to 24 days). GCF and saliva samples were collected and 
clinical parameters including PlI and BOP were recorded at each menstrual phase.  
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 Salivary estrogen and progesterone levels were analyzed to determine exact 
menstrual cycle days. GCF levels of IL-6, PGE2, tissue plasminogen activator and 
plasminogen activator inhibitor were measured by enzyme-linked immunosorbent 
assay. The percentages of sites with BOP were significantly higher in menstrual phase 
(60.85-18.36) and ovulation phase (58.92-25.04) than in the premenstrual (40.12-
20.10) phase in the gingivitis group (P < 0.001; repeated measures analysis of 
variance), whereas it was similar for all phases in the healthy group (P > 0.05; 
repeated measures analysis of variance). GCF levels of IL-6 were significantly 
elevated in gingivitis patients compared to healthy subjects in all phases (P=0.004, 
P=0.041, and P=0.046 for menstrual phase, ovulation phase, and premenstrual phase, 
respectively; Mann-Whitney U test).  
 GCF levels of IL-6, PGE2, tissue plasminogen activator and plasminogen 
activator inhibitor were unchanged in different menstrual phases in both groups (P 
>0.05; Friedman test). In conclusion, the present study suggests that changes in the 
sex steroid hormones during menstrual cycles might have a limited effect on the 
inflammatory status of gingiva, but GCF cytokine levels were not affected. 
 Lai et al (2010)103 in an in vitro study investigated the effects of areca nut 
extract on the production of COX-2 and the inflammatory mediator PGE2 produced by 
PMNs. The possible effects of Areca nut extract on the production of COX-2 were 
examined using Western blotting analysis. The viability and production of PGE2 of 
treated PMNs were determined using the propidium iodide staining method and the 
competition enzyme assay, respectively.  
 The possible pathways involved were also examined using the COX-2 
inhibitor (NS398), the intracellular calcium chelator 1,2-bis(2-aminophenoxy) ethane-
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N, N, N9, N9-tetraacetic acid tetrakis (acetoxymethyl ester) (BAPTA-AM), the p38 
mitogen-activated protein kinase inhibitor (SB203580), and the extracellular signal-
regulated protein kinase inhibitor (U0126).  
 Results showed that areca nut extract significantly induced the production of 
PGE2 in a time- and concentration-dependent manner. This induction resulted from an 
increased expression of COX-2. Moreover, the application of BAPTA-AM, 
SB203580, and U0126 statistically significantly suppressed the induction of PGE2. In 
conclusion, areca nut extract induced the production of PGE2. The activation of the 
intracellular calcium concentrations, p38 MAPK, and ERK may be involved in the 
inducing effects of areca nut extract on PMNs. The findings suggest that areca nut 
chewing may induce an inflammatory response and affect the periodontal health of 
consumers. 
 Offenbacher S (2010)104 performed a human study to characterize the 
changes in 33 biomarkers within the GCF during the 3-week induction and 4-week 
resolution of stent-induced, biofilm overgrowth mediated, experimental gingivitis in 
humans. Experimental gingivitis was induced in 25 subjects for 21 days followed by 
treatment with a sonic powered toothbrush for 28 days.  
 Clinical indices recordings and GCF collection were done weekly during 
induction and biweekly during resolution. Samples were analyzed using a bead-based 
multiplexing analysis for the simultaneous measurements of 33 biomarkers within 
each sample including cytokines, MMPs and adipokines.  
 PGE2 was measured by ELISA. Statistical testing using general linear models 
with structured covariance matrices were performed to compare stent to contralateral 
(nonstent) changes in clinical signs and in biomarker levels over time. Gingivitis 
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induction was associated with a significant 2.6-fold increase in IL 1-beta, a 3.1 fold 
increase in IL 1-alpha, and a significant decrease in multiple chemokines as well as 
MMP -1,- 3 and 13.  
 All changes in clinical signs and mediators rebounded to baseline in response 
to treatment in the resolution phase. In conclusion, stent-induced gingivitis is 
associated with marked, but reversible increases in IL1-alpha and 1-beta with 
suppression of multiple chemokines as well as selected mat MMPs. 
 Kumar et al (2013)105 reported that the measurement of PGE2 level in GCF 
has been shown to an indication of periodontal tissue destruction. The collection of 
GCF is a non-invasive procedure and hence developing PGE2 chair side diagnostic 
kits to measure PGE2 levels can not only estimate the nature of periodontal disease 
before treatment, but also after treatment. Changes in GCF PGE
2 
levels following 
anti-plaque measures appears to have been less explored in the periodontal literature 
and need further exploration.  
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 This study was conducted at the outpatient section of the Department of 
Periodontics, Sri Ramakrishna Dental College & Hospital, Coimbatore. Only patients 
who provided informed consent were recruited into the study.  
STUDY DESIGN AND PATIENT SELECTION  
This is a single center, triple blinded, randomized controlled clinical study. The 
subjects admitted to study had to satisfy the following criteria:  
Inclusion criteria: 
   1. Age: More than 18 years and less than 45 years      
   2. Moderate to severe gingivitis (Loe & Silness GI scores between 1.1-3.0)      
Exclusion criteria:   
     1. Pregnant and lactating women 
     2. Any systemic disease 
     3. Currently on any long term medications 
     4. Any periodontal treatment during the past 6 months 
     5. Smoking or other forms of use of tobacco    
RANDOMIZATION & ALLOCATION CONCEALMENT      
      Twenty nine patients out of 36 out-patients (Drop outs–7 patients) with 
gingivitis (Fig. 6), who met the selection criteria and provided informed consent were 
randomized to 3 groups i.e. Group A mouthwash, Group B mouthwash, Group C 
mouthwash. Each patient is provided with any of the three types of mouthwashes i.e 
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CHX mouthwash or herbal oil mouthwash or Placebo mouthwash containing mint 
flavored distilled water. All the selected patients were given mouthwash which was 
blinded and assigned randomly in a sequential order. For example, the first patient, 
second patient and the third patient were given Group A mouthwash, Group B 
mouthwash and Group C mouthwash respectively. The groups to which the patients 
were randomized were written against their serial number in a small piece of paper 
and placed in a sealed envelope.    
STUDY ETHICS AND SAFETY  
 The conduct of this clinical trial followed the principles in the Declaration of 
Helsinki (2008). Approval from the Institutional Review Board and Ethical 
Committee of Sri Ramakrishna Dental College and Hospital was obtained prior to 
implementation.  
ARMAMENTARIUM  
Diagnostic instruments  
Mouth mirror, explorer, tweezer, periodontal probe, cotton rolls and pledgets. (Fig. 7) 
 Sample collection and storage   
 Micro-capillary pipette (1-5μl) (Sigma-Aldrich Co., St. Louis, USA)TM, Sterile 
storage vials, Vial container and Ultralow temperature freezer (-70oC) for storing 
GCF samples and Ultralow temperature freezer (-35oC) for storing PGE2 standard and 
conjugate. (Fig. 11).  
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ELISA analysis  
 PGE2 ELISA kit (Fig.12), ELISA microplate reader (Fig. 18.), micro-pipettes 
of varying calibrations with tips. (Fig 12) 
PGE2 ELISA kit Contents: 
1. Goat anti-Mouse IgG Microtiter Plate, (One Plate of 96 Wells)- is a plate using 
break-apart strips coated with goat antibody specific to mouse IgG. 
2. PGE2 EIA Conjugate (6 mL) is a blue solution of alkaline phosphatase conjugated 
with PGE2 
3. PGE2 EIA Antibody (6 mL) is aA yellow solution of a monoclonal antibody to 
PGE2. 
4. Assay Buffer (30 mL) is a Tris buffered saline containing proteins and sodium 
azide as preservative. 
5. Wash Buffer Concentrate (30 mL) is a Tris buffered saline containing detergents. 
6. PGE2 Standard, (0.5 mL) is a solution of 50,000 pg/mL PGE2 
7. pNpp Substrate (20 mL) is a solution of p-nitrophenyl phosphate in buffer which is 
ready to use. 
8. Stop Solution (5 mL) is a  solution of trisodium phosphate in water. It should be 
kept tightly capped as it is caustic in nature. 
9. PGE2 Assay Layout Sheets, one each was provided 
10. Plate Sealer, one each was provided 
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 Drug dispensing  
Amber colored containers and measuring cup to dispense mouthwash. (Fig. 8). 
GINGIVAL EXAMINATION  
In every examination, the following clinical parameters were scored:  
Gingival health was evaluated using  
1. GI system (Loe and Silness 1963).9 
2. Plaque was assessed using the criteria of the PlI system (Silness and Loe 1964).10           
3. Gingival Bleeding was assessed using Modified Sulcular Bleeding Index (mSBI) 
(Mombelli et al, 1987).11 
  GCF COLLECTION  
 Gingival clinical examination was performed one day prior to GCF sample 
collection to avoid stimulation of the gingival tissues and blood contamination. The 
gingival status of the recruited patients was visually examined to assess possible GCF 
collection sites.  
 Next day, suitable sampling site which correlates with greatest gingival 
inflammation was selected, air dried and isolated with cotton rolls. The supragingival 
plaque was removed to avoid contamination and blocking of micro-capillary pipette. 
The tip of the color-coded, calibrated (1-3μl) volumetric micro-capillary pipette 
(Sigma-Aldrich Co., St. Louis, USA)TM was placed at the entrance of the gingival 
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crevice. (Fig. 9.) The GCF samples which were entrapped with air bubbles or 
contaminated with blood or saliva were discarded and fresh samples were collected.12 
 Each micro-capillary pipette containing GCF was placed inside separate sterile 
tubes (Fig. 10) and stored at -70° C temperature8  in an ultralow temperature freezer 
(HERA freeze -86°C Basic Upright Freezers, Thermo Fisher Scientific India Pvt. Ltd. 
Mumbai, India) in Department of Microbiology, Sri Ramakrishna Hospital, 
Coimbatore until further analysis. (Fig. 11) 
MOUTHRINSES  
The mouthrinses tested in the present trial were:  
1. 0.2% CHX Digluconate (Hexidine mouthwash, ICPA Health Products 
LTD,Coimbatore) 
2. Herbal mouthrinse (Arimedadi Taila) (Indian Medicines Pharmaceutical 
Corporation Ltd, (A Government of India Enterprise), Almora, Uttarakhand. 
3. Placebo mouthrinse containing Mint flavoured  distilled water (Prepared by 
adding 4 drops of mint flavouring agent to 300 ml of  distilled water). 
CHX, herbal oil mouthrinses and Mint flavored water mouthrinse were packed in 
individual amber colored containers of 300 ml each and was provided with a 
measuring cup.  
ALLOCATION PROCEDURE  
 After collection of GCF samples, the patient was referred to the drug 
dispensing section of the Pharmacy of Sri Ramakrishna Dental College & Hospital, 
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Coimbatore, where the sealed envelope corresponding to the patient’s serial number 
was opened by a pharmacist who delivered the mouthwash mentioned in the envelope 
and also provided instructions pertaining to its use.  
RINSING PROCEDURES  
 CHX group - rinsing with 10 ml of a mouthrinse containing 0.2% CHX 
Digluconate twice daily for 1 minute. The patients were instructed to rinse 30 minutes 
after brushing, and to avoid eating or rinsing the mouth with water for 30 minutes 
after the procedure.13 
  Herbal mouthrinse -.10 ml of Arimedadi Taila to be sipped, sucked, and 
swished between the teeth for 10-15 minutes (until the viscous liquid turns thin and 
milky white), twice daily after brushing. It should not be swallowed. It should be 
followed by washing with plenty of water.14 
 Mint flavored water group - rinsing with 10 ml of a mint flavored water 
mouthrinse twice daily for 1 minute. The patients were instructed to rinse 30 minutes 
after brushing, and to avoid eating , drinking or rinsing the mouth with water for 30 
minutes after the procedure. 
FOLLOW UP  
 The patients were instructed to report after two weeks, GCF sample collection 
procedures were performed and the patients were re-examined to observe any changes 
in the gingival clinical parameters that were measured at baseline. At second week 
they were given fresh mouthwashes after returning the empty bottles.  
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 At the end of fourth week, similar GCF sample collection procedures were 
performed and the patients were re-examined to observe any changes in the gingival 
clinical parameters that were measured at second week.    
ELISA ANALYSIS  
 The biochemical evaluations were done at the Department of Biochemistry, 
Bioline Laboratory, Coimbatore, Tamilnadu.    
Assay Procedure:  
 On the day of ELISA analysis, GCF samples which were stored at -70° C were 
thawed and brought to room temperature. And all reagents should be brought to room 
temperature for at least 30 minutes prior to opening.   
1. PGE2 Standard preparation:  
 50,000 pg/mL PGE2 standard solution was allowed to warm to room 
temperature. Seven, 12 x 75 mm glass tubes were labelled #7 till #1. 1ml of 
standard diluent was pipetted (Assay Buffer or Tissue Culture Media) into 
tube #7. 500μl of standard diluent was pipetted into tubes #6 till  #1. 50μl of 
diluent was removed and 50μl of the 50,000 pg/mL standard was added to 
tube #7.  It was vortexed thoroughly. 500μl of solution from tube #7 was 
added  to tube #6 and vortexed thoroughly. 500μl of solution from tube #6 was 
added to tube #5 and vortexed. This was continued for tubes #4 through #1. 
The concentration of PGE2 in tubes #7 through #1 was 2,500, 1,250, 625, 313, 
156, 78.1 and 39.1 pg/mL respectively. (Fig.14) 
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2. Wash buffer was prepared by diluting 5mL of the supplied concentrate with 95 
mL of deionized water. 
3. The Assay Layout Sheet was referred in order to determine the number of 
wells that were to be used . 
4. From each micro-capillay pipette 1μl of the GCF sample was transferred to 99 
μl of standard human assay buffer, which was provided with the ELISA kit by 
passing the plunger through the micro-capillary pipettes.(Fig. 15) 
5. 100 µL of standards #1 through #7 was pipetted into the appropriate wells. 
6.  100 µL of the samples were pipetted into the appropriate wells. 
7. 50 µL of blue conjugate (Fig. 16.a) was pipetted into each well, except the 
Blank wells. 
8.  50 µL of yellow antibody (Fig. 16.b) was pipetted into each well, except the 
Blank. Every well used was required to be green in color.  
9. The plate was incubated at room temperature on a plate shaker for 2 hours at 
~500 rpm. The plate was covered with the plate sealer provided.. 
10. The contents of the wells were emptied and manually washed by adding 400 
µL of wash solution to every well. The wash was repeated 2 more times for a 
total of 3 washes. 
11. After the final wash, the wells were emptied and aspirated, and the plate was 
tapped firmly on a lint free paper towel to remove any remaining wash buffer. 
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12. 200 µL of the pNpp substrate solution was added to every well and incubated 
at   room temperature for 45 minutes without shaking 
13.  50 µL of stop solution (Fig.16.c) was added to every well. This stopped the 
reaction and the plate was read immediately. 
14. The absorbance was measured using a microplate reader (Model 680 
microplate reader, Bio-Rad Laboratories Inc, USA) after the recommended 
incubation process. (Fig. 17). Standard curve was plotted by the reader. 
(Graph.1). Sample concentrations may be calculated off Net OD values using 
desired curve fitting.  The plate reader was blanked against the Blank wells 
and the optical density was read at 405 nm, with correction at 590 nm. The 
minimal detectable dose of PGE2 was 13.4 pg/mL.  
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DEPARTMENT OF PERIODONTICS  
SRI RAMAKRISHNA DENTAL COLLEGE & HOSPITAL  
FORM I – SCREENING PROFORMA  
“A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF 
ARIMEDADI OIL PULLING IN PLAQUE INDUCED GINGIVITIS AND ITS 
EFFECT ON METABOLIC MARKER IN GINGIVAL CREVICULAR FLUID”. 
1. Serial No. _________________Code No._____________________ 
2. Name of the subject ______________________________________ 
 
3. Date of Birth  Age (in years)                
 
4. Postal address___________________________________________ 
________________________________________________________ 
Telephone No.____________________________________________ 
5. CRITERIA OF INCLUSION:       
        Yes  No 
 
   1. Age: More than 18 years and less than 45 years 
 
   2. Moderate to severe gingivitis (Loe & Silness  
       Gingival Index scores between1.1-3.0)     
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6. CRITERIA OF EXCLUSION     Yes  No 
 
     1. Pregnant and lactating women 
     2. Any systemic disease 
     3. Currently on any long term medications 
     4. Any periodontal treatment during the past 6 months 
     5. Smoking or other forms of use of tobacco 
 
7. Quantity of mouth rinse provided to the patient   ____________________________ 
Dated  ______   Signature of the Doctor _________________________ 
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FORM 1A-HISTORY PROFORMA 
1. Educational status 
Illiterate  Educated  
If educated then mention level of education__________________________ 
2. Occupation______________________________________________ 
3. Monthly family income (in INR) ____________________________ 
4. Chief complaint with duration (if any) in weeks. 
                                                                 Absent                   Present                 Duration 
 
 
 1. Bleeding gums       
   
 
 2. Bad breath   
    
   
 3. Pain in gums   
 
 4.Bleeding on 
 brushing/eating  only 
 
 5. Itching of gums 
    
   
 6. Swelling in gums 
 
 7. Pus discharge from 
 gums 
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 8. Any other complaint’s (Specify)   ________________________________ 
5. Personal history: 
 1. Diet:      Veg                Non –veg                      Mixed 
 2. Brushing habit:_______________________________________________ 
 3. Any other (specify)____________________________________________  
Date_______     Signature of the doctor____________________ 
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DEPARTMENT OF PERIODONTICS 
SRI RAMAKRISHNA DENTAL COLLEGE & HOSPITAL 
 
FORM II – CLINICAL ASSESSMENT 
 
“A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF 
ARIMEDADI OIL PULLING IN PLAQUE INDUCED GINGIVITIS AND ITS 
EFFECT ON METABOLIC MARKER IN GINGIVAL CREVICULAR FLUID”. 
Baseline 
 CLINICAL PARAMETERS ASSESSMENT: 
                                 17    16    15   14      13  12   11   21   22   23        24   25   26   27   
                                47    46    45   44      43   42   41   31   32   33         34   35   36   37    
                        
         
                   
 
 
 
 
 
 
 
 
 
 
  CONTOUR 
CONSISTENCY 
SURFACE 
TEXTURE 
BLEEDING ON 
PROBING 
COLOR 
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 CLINICAL INDICES: 
GINGIVAL INDEX (LOE & SILNESS, 1963) 
   17   16   15   14   13   12   11   21   22   23   24   25   26   27 
B                                           
P               
 
   47   46   45   44   43   42   41   31   32   33   34   35   36   37 
B                                           
L               
 
Calculation:                                            = 
 
 
Inference: …………………...                 Mild gingivitis: 0.1 - 1.0 
                                                 Moderate gingivitis: 1.1 – 2.0 
                Severe gingivitis: 2.1 – 3.0 
PLAQUE INDEX (SILNESS & LOE, 1964) 
 
   17   16   15   14   13   12   11   21   22   23   24   25   26   27 
B                                           
P               
 
   47   46   45   44   43   42   41   31   32   33   34   35   36   37 
B                                           
L               
           
           
           
         
 
Calculation:                                                                                                                                                                                                                                                    =      
 
                                                                                                                                                     
       Sum of score of each teeth 
   Total number of teeth examined  
       Sum of score of each teeth 
   Total number of teeth examined  
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Inference: ……………………..                 Excellent: 0    
       Good: 0.1 - 1.0  
                                               Fair: 1.1 – 2.0 
        Poor: 2.1 – 3.0 
BLEEDING INDEX: (MODIFIED SULCULAR BLEEDING INDEX, MOMBELLI 
ET AL, 1987) 
17 16 15 14 13 12 11 21 22 23 24 25 26 27 
              
              
47 46 45 44 43 42 41 31 32 33 34 35 36 37 
                                              
=  
Calculation:                        = 
 
Date ___________ Signature of the Doctor  ________________________________ 
 
 
 
 
 
    
       Sum of score of each teeth 
   Total number of teeth examined  
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DEPARTMENT OF PERIODONTICS 
      SRI RAMAKRISHNA DENTAL COLLEGE & HOSPITAL  
 
                   FORM II – CLINICAL ASSESSMENT 
 
“A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF 
ARIMEDADI OIL PULLING IN PLAQUE INDUCED GINGIVITIS AND ITS 
EFFECT ON METABOLIC MARKER IN GINGIVAL CREVICULAR FLUID”. 
 
          II week      IV week    
1. Serial No. 
 
2. Code No. of the subject_____________________________________ 
 
 
3. Name of the subject ________________________________________ 
 
4. Date of birth   
    
Age (in years)  
 
5. Date of assessment_________ 
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6. CLINICAL SYMPTOMS: 
       Absent      Present 
    
 1. Bleeding gums 
 2. Bad breath 
 3. Pain in gums 
 4. Bleeding on brushing or eating only 
 5. Itching of gums 
 6. Swelling in gums 
 7. Pus discharge from gums 
 
 8. Other complaints, if any (specify) _________________________________ 
 _______________________________________________________________
 _______________________________________________________________
 _______________________________________________________________ 
 
 
7.   
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CLINICAL PARAMETERS ASSESSMENT:                        
                                 17    16    15   14      13  12   11   21   22   23        24   25   26   27   
                                47    46    45   44      43   42   41   31   32   33        34   35   36   37    
 
 
 
  
 
 
 
 
 
 
 
    
  
 
8. Adverse reactions:   Yes  No  
 
9. Overall clinical assessment by the doctor: 
 
Improved  No change D       Deteriorated  
 
 
   COLOR 
     CONTOUR 
CONSISTENCY 
SURFACE 
TEXTURE 
BLEEDING 
ON PROBING 
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10. Overall impression of well being by the subject: 
Complete cure      Improved   No change    Deteriorated  11. 
11. Status of the patient: 
 
Continuing   
Drop out    
Reason_______________________________________________________________
____________________________________________________________________ 
CLINICAL INDICES: 
GINGIVAL INDEX (LOE & SILNESS, 1963) 
   17   16   15   14   13   12   11   21   22   23   24   25   26   27 
B                                           
P               
 
   47   46   45   44   43   42   41   31   32   33   34   35   36   37 
B                                           
L               
 
 
Calculation: 
  = 
 
Inference: ………………….                            Mild gingivitis: 0.1 - 1.0 
                                                  Moderate gingivitis: 1.1 – 2.0   
                                                  Severe gingivitis: 2.1 – 3.0 
 
       Sum of score of each teeth 
   Total number of teeth examined  
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PLAQUE INDEX (SILNESS & LOE, 1964) 
 
   17   16   15   14   13   12   11   21   22   23   24   25   26   27 
B                                           
P               
 
   47   46   45   44   43   42   41   31   32   33   34   35   36   37 
B                                           
L               
 
 
Calculation:   = 
Inference: …………………                               Excellent: 0  
        Good: 0.1 - 1.0 
                                               Fair: 1.1 – 2.0  
                                               Poor: 2.1 – 3.0 
BLEEDING INDEX : (MODIFIED SULCULAR BLEEDING INDEX, MOMBELLI  
ET AL, 1987) 
17 16 15 14 13 12 11 21 22 23 24 25 26 27 
              
              
47 46 45 44 43 42 41 31 32 33 34 35 36 37 
=                      
 
Calculation:                                                                                            =  
             
Date _______      Signature of the Doctor__________________ 
       Sum of score of each teeth 
   Total number of teeth examined  
       Sum of score of each tooth      
  Total number of teeth examined  
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DEPARTMENT OF PERIODONTICS 
SRI RAMAKRISHNA DENTAL COLLEGE & HOSPITAL 
PATIENT INFORMATION SHEET 
 “A randomized triple blind controlled clinical trial to evaluate the efficacy of 
arimedadi oil pulling in plaque induced gingivitis and its effect on metabolic marker 
in gingival crevicular fluid”. 
What is the study about?  
 The present study is aimed to evaluate the efficacy of Arimedadi Taila in the 
management of gum diseases. Arimedadi Taila is a medicated oil which contains 
ayurvedic medicaments.  
What will you have to do?  
 As a participant of this study, you must rinse your mouth twice daily with 10 
ml of the medicated oil or a regular allopathic mouthrinse or a placebo mouthrinse for 
a period of one month. The interval between subsequent visits during the treatment 
will be 2 week. At each visit you will be supplied with sufficient quantities of drug to 
last until your next visit (2 week). After completion of rinsing for 1 month, you will 
be required to visit the hospital for necessary check up.  
 Before you start treatment, during the first visit to the clinic, you will undergo 
a complete oral examination and there after on next day about 1 μl fluid that gets 
secreted in your gums will be collected. The same procedures will be repeated at II 
week and IV week.  
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   DEPARTMENT OF PERIODONTICS  
  SRI RAMAKRISHNA DENTAL COLLEGE & HOSPITAL  
“A randomized triple blind controlled clinical trial to evaluate the efficacy of 
arimedadi oil pulling in plaque induced gingivitis and its effect on metabolic marker 
in gingival crevicular fluid”. 
     CONSENT FORM  
    CERTIFICATE BY INVESTIGATOR  
I certify that I have disclosed all details about the study in the terms easily understood 
by the patient.  
Date_____________  
Signature_____________________  
Name_______________________  
CONSENT BY SUBJECT  
 I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial and the nature of drug treatment and follow-up, including 
the laboratory investigations to be performed to monitor and safeguard my body 
functions.  
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 I am also aware of my right to opt out of the trial at any time during the course 
of the trial without having to give the reasons for doing so. I, exercising my free 
power of choice hereby give my consent to be included as a subject in this clinical 
trial which involves the evaluation of Arimedadi Taila in plaque induced gingivitis.  
           
Date________________   Signature or Thumb impression  
  
Date________________                               Signature of witness_____________  
           
      Name________________________ 
       
      Relationship___________________    
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DEPARTMENT OF PERIODONTICS   
SRI RAMAKRISHNA DENTAL COLLEGE & HOSPITAL  
FORM 3 – LABORATORY INVESTIGATIONS 
“A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF 
ARIMEDADI OIL PULLING IN PLAQUE INDUCED GINGIVITIS AND ITS 
EFFECT ON METABOLIC MARKER IN GINGIVAL CREVICULAR FLUID”. 
1. Serial No.  
2. Code No. of the subject_______________________________  
(to be filled later by the investigator)  
3. Samples received on _____________________________  
4. Date of assessment________________________________  
5. Lab investigations________________________________ 
  
  
Date______________     Signature of the lab technician 
INFLAMMATORY 
BIOMARKER  
 QUANTITY  
 COMMENTS 
 
PROSTAGLANDIN E2    
  GCF SAMPLE 1 
   
  
 GCF SAMPLE 1 
 
  
 GCF SAMPLE 1 
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STATISTICAL ANALYSIS :  
 The distribution of PGE2 levels in GCF were examined to identify potential 
outliers. Changes in GI scores, PlI scores, Bleeding scores and GCF PGE2 levels at 
baseline, II week and IV week following mouth rinsing was assessed using paired 
samples ‘t’ test and the statistical significance was determined using two-sided p 
 
 
 
values (p<0.05). Comparison of CHX and OP group (P values) was assessed by 
using independent samples ‘t’ test and P <0.05.was considered statistical significant.  
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Fig. 11. Ultra low temperature freezers that were used for storing samples 
at -70◦C and -35◦C 
 
 
 
Fig. 12. ELISA kit 
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Fig. 13. Micro-pipettes used for transfering reagents and samples 
 
 
 
 
 
 
 
 
 
 
 
 
             Fig. 14. Addition of standard            Fig. 15. Addition of GCF 
                 and assay buffer                                   sample  
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Fig. 16. Different steps during ELISA- following addition of  
 (a) Conjugate             (b) Antibodies         (c) Stop solution  
 
 
Fig .17. Microplate reader used for measuring absorbance 
 
 
 
 
 
 
  
       
 
 
Graph 1: Standard graph 
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 The efficacy of Arimedadi Taila on gingivitis patients has been studied by 
evaluating its effect on clinical and biochemical parameters and the observations are as 
follows - 
1. BASELINE SAMPLE CHARACTERISTICS:  
 The mean age (± SD) of participants with gingivitis was 27.36 ± 6.76 years (18 – 
45 yrs). Out of 29 patients number of males were 15 (48.28%) and females were 14 
(58.72%). Sample collection was done at baseline, II week and IV week from 10 patients 
in Oil pulling group, 10 patients in CHX group and 9 patients in Placebo group. The data 
pertaining to the subject variables for all the 3 groups i.e., Age, sex and brushing 
frequency/day have been summarized in Tab. 5.  
2. BASELINE AND POST-INTERVENTION (II WEEK AND IV WEEK) 
CLINICAL PARAMETERS AND PGE2 LEVELS IN GINGIVITIS PATIENTS:   
 The inflammatory status of the gingiva around the tooth with greatest 
inflammation (from which the GCF sample was taken) was assessed using the Gingival 
Index (Loe & Silness, 1963). The overall Gingival Index (Loe & Silness, 1963), Plaque 
Index (Silness & Loe, 1964) and Modified Sulcular Bleeding Index (Mombelli et al, 
1987) score have been summarized in Tab. 6, which also lists the PGE2 levels in GCF of 
the corresponding patient, both at baseline, second week and fourth week.    
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3. COMPARISON OF BASELINE AND POST-INTERVENTION VALUES 
FOLLOWING MOUTHRINSING:  
b. Changes in Plaque index (PlI) score post-intervention:    
 In the CHX group, PlI score at baseline, II week and IV week were 1.808, 1.504, 
and 1.163 respectively. Overall, the PlI score decreased by 16.79% from baseline (1.808) 
to II week (1.504), and 22.69% from II week (1.504) to IV week (1.163). This reduction 
was statistically significant (P=0). And also, when the PlI score was compared from 
baseline to IV week, there was a reduction of 35.67%, which was statistically also 
significant (P=0).  
 In the Oil pulling group, PlI score at baseline, II week and IV week were 1.910, 
1.851 and 1.793 respectively. It decreased by 3.07% from baseline (1.910) to II week 
(1.851) and by 3.13% from II week (1.851 ) to IV week (1.793), and this reduction was 
statistically significant (P=0). Furthermore, when the PlI score was compared from 
baseline to IV week, there was a reduction of 6.11%, which was also statistically 
significant (P=0).  
 In the Placebo group, PlI score at baseline, II week and IV week were 1.996, 
1.998 and 2.043 respectively. The PlI score increased by 0.10% from baseline (1.996) to 
II week (1.998), but this increase was not significant (P=0.719). However, when the PlI 
score at II week (1.998) and IV week (2.043) were compared, it further increased by 
2.29% at IV week and this increase was statistically significant (P=0.012). And also, 
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when the PlI score was compared from baseline to IV week, there was an increase of 
2.39%, which was also statistically significant (P=0.025). 
 Overall, from baseline to IV week, when the Placebo, CHX and Oil pulling 
groups were compared, the percentage reduction in PlI score was highest in the CHX 
group (35.67%), when compared to the Oil pulling group (6.11%). In contrast, the 
Placebo group demonstrated an overall increase in PlI score (2.39%). The data related to 
the same has been depicted in Fig. 19 and Tab. 7.  
 Finally, from baseline to II week and IV week, when the reduction in PlI were 
compared for the CHX and Oil pulling groups, the difference was statistically significant 
(P=0). (Tab. 8.) 
b. Changes in Gingival Index (GI) score post-intervention:   
 In the CHX group, GI score at baseline, II week and IV week were 1.727, 1.395, 
1.187.respectively. Overall, the GI score decreased by 19.19% from baseline (1.727) to II 
week (1.395), and 14.94% from II week (1.395) to IV week (1.187). This reduction was 
statistically significant (P=0). And also, when the GI score was compared from baseline 
to IV week, there was a reduction of 31.26%, which was also statistically significant 
(P=0).  
 In the Oil pulling group, the GI score at baseline, II week and IV week were 
1.808, 1.742 and 1.645.respectively The GI score decreased by 3.67% from baseline 
(1.808) to II week (1.742), and this reduction was statistically significant (P=0.004). 
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From II week (1.742) to IV week (1.645), the GI score further decreased by 5.56% and 
this decrease was statistically significant (P=0.001). And also, when the GI score was 
compared from baseline to IV week, there was a reduction of 9.03%, which was also 
statistically significant (P=0).  
 In the Placebo group, GI score at baseline, II week and IV week were was 1.936, 
1.939 and 1.996 respectively. It increased by 0.15% from baseline (1.936) to II week 
(1.939), but this increase was not significant (P=0.674). However, when the GI score at II 
week (1.939) and IV week (1.996) were compared, it further increased by 2.96% at IV 
week and this increase was statistically significant (P=0.003). Furthermore, when the GI 
score was compared from baseline to IV week, there was an increase of 3.12%, which 
was also statistically significant (P=0.011). 
 Overall, from baseline to IV week, when the Placebo, CHX and Oil pulling 
groups were compared, the percentage reduction in GI score was highest in the CHX 
group (31.26%), when compared to the Oil pulling group (9.03%). In contrast, the 
Placebo group demonstrated an overall increase in GI score (3.12%). The data related to 
the same has been depicted in Fig. 20 and Tab. 7.   
 Finally, from baseline to II week and IV week, when the reduction in GI scores 
were compared for the CHX and Oil pulling groups, the difference was statistically 
significant (P=0). (Tab. 8.) 
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c. Percentage reduction in gingival bleeding post-intervention:  
 The data pertaining to the difference between the percentage of sites showing 
signs of bleeding on probing (BOP) at baseline and after intervention has been 
summarized in Fig. 21 and Tab. 7. In the CHX group, bleeding score at baseline, II week 
and IV week were 79.166%, 65.952% and 51.785% respectively. Overall, the bleeding 
sites decreased by 16.69% from baseline to II week, and by 21.48% from II week to IV 
week. This reduction was statistically significant (P=0). And also, when the bleeding 
score was compared from baseline to IV week, there was a reduction of 34.59%, which 
was also statistically significant (P=0).  
 In the Oil pulling group, bleeding score at baseline, II week and IV week were 
78.214%, 75.952% and 73.571% respectively. It decreased by 2.89% from baseline to II 
week and by 3.13% from II week to IV week, this reduction was statistically significant 
(P=0). Furthermore, when the bleeding score was compared from baseline to IV week, 
there was a reduction of 5.94%, which was also statistically significant (P=0).  
 In the Placebo group, the bleeding score at baseline, II week and IV week were 
73.280%, 73.809% and 76.290% respectively. It increased by 0.72% from baseline to II 
week, but this increase was not significant (P=0.104). However, when the bleeding score 
at II week and IV week were compared, it further increased by 3.36% at IV week and this 
increase was statistically significant (P=0.005). Furthermore, when the Bleeding score 
was compared from baseline to IV week, there was an increase of 4.11% which was also 
statistically significant (P=0.009). 
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 Overall, from baseline to IV week, when the Placebo, CHX and Oil pulling 
groups were compared, the percentage reduction in bleeding score was highest in the 
CHX group (34.59%), when compared to the Oil pulling group (5.94%). In contrast, the 
Placebo group demonstrated an overall increase in bleeding score (4.11%).  
 Finally, from baseline to II week and IV week, when the reduction in BOP scores 
were compared for the CHX and Oil pulling groups, the difference was statistically 
significant (P=0). (Tab. 8.)  
d. Changes in GCF PGE2 levels post-intervention:  
 The changes in GCF PGE2 levels (Pg/mL), from baseline to post-intervention 
have been summarized in Tab. 7 and Fig. 22. In the CHX group, crevicular PGE2 levels 
at baseline, II week and IV week were 200.899 Pg/mL, 147.028 Pg/mL and 103.106 
Pg/mL respectively. It decreased by 26.81% from baseline to II week and by 29.87% 
from II week to IV week. This reduction was statistically significant (P=0). Furthermore, 
when the PGE2 levels were compared from baseline to IV week, there was a reduction of 
48.68%, which was also statistically significant (P=0).  
 In the Oil pulling group, crevicular PGE2 levels at baseline, II week and IV week 
were 194.929 Pg/mL, 182.677 Pg/mL and 173.286 Pg/mL respectively. It decreased by 
6.29% from baseline to II week, and this decrease was statistically significant (P=0). 
From II week to IV week, crevicular PGE2 levels decreased by 5.14% and this reduction 
was statistically significant (P=0.001). And also, When the PGE2 levels were compared 
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from baseline to IV week, there was a reduction of 11.10%, which was also statistically 
significant (P=0).  
 In the Placebo group, the crevicular PGE2 levels at baseline, II week and IV week 
were 171.439 Pg/mL, 173.351 Pg/mL and 186.838 Pg/mL respectively. It increased by 
1.11% from baseline to II week, but this increase was not significant (P=0.674). 
However, when the PGE2 levels at II week and IV week were compared, it further 
increased by 7.78% at IV week and this increase was statistically significant (P=0.001). 
Furthermore, when the PGE2 levels were compared from baseline to IV week, there was 
an increase of 8.98%, which was also statistically significant (P=0.003). 
 Overall, from baseline to IV week, when the Placebo, CHX and Oil pulling 
groups were compared, the percentage reduction in crevicular PGE2 levels was highest in 
the CHX group (48.68%), when compared to the Oil pulling group (11.10%). In contrast, 
the Placebo group demonstrated an overall increase in GCF PGE2 levels (8.98%).  
 Finally, from baseline to II week and IV week, when the reduction in GCF PGE2 
levels were compared for the CHX and Oil pulling groups, the difference was statistically 
significant (P=0). (Tab. 8.) 
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Tab. 5. Baseline sample characteristics 
     
Parameter 
 
No. of 
Patients 
No. of 
Males 
No. of 
Females 
Brushing    
frequency/day 
Age (years) 
(Range 18-45) 
–
Once Twice Mean±S.D 
Total 29 15 14 19 10 27.36± 6.76 
Oil pulling 10 5 5 6 4 25.9 ± 4.09 
CHX 10 5 5 7 3 30.67 ± 6.95 
Placebo 9 5 4 6 3 25.67 ± 8.29 
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 Tab. 6. Baseline and post-intervention clinical parameters and GCF PGE2 levels 
 
 
Patient Group 
Tooth with 
greatest GI 
scores 
Period Pll 
scores 
GI  
scores 
BOP 
scores 
GCF 
PGE2 
levels 
(pg/mL) 
1 OP 2.25 
Baseline 2.035 2.071 85.714 198.009 
II week 1.964 2.000 82.142 186.481 
IV week 1.892 1.892 80.952 174.721 
2 CHX 2.5 
Baseline 1.892 2.446 85.714 270.619 
II week 1.535 1.750 72.619 194.418 
IV week 1.178 1.642 59.523 140.407 
3 PL 2.5 
Baseline 2.607 2.205 88.095 235.210 
II week 2.616 2.223 89.285 240.120 
IV week 2.669 2.294 92.857 266.762 
4 OP 2.75 
Baseline 1.562 2.526 95.238 318.241 
II week 1.508 2.428 94.047 299.145 
IV week 1.500 2.285 90.476 280.051 
5 CHX 2.5 
Baseline 1.607 2.044 79.761 188.000 
II week 1.333 1.705 67.857 137.642 
IV week 0.991 1.616 55.952 98.004 
6 PL 2.25 
Baseline 1.616 1.910 69.047 157.582 
II week 1.616 1.919 70.238 161.280 
IV week 1.625 2.035 75.900 174.721 
7 PL 2.5 
Baseline 2.241 2.232 80.952 211.683 
II week 2.250 2.250 80.952 213.842 
IV week 2.330 2.303 84.523 235.210 
8 OP 2.0 
Baseline 1.830 1.919 92.857 306.015 
II week 1.794 1.892 89.285 287.642 
IV week 1.759 1.767 86.904 268.280 
9 CHX 1.5 
Baseline 1.437 1.133 58.333 133.972 
II week 1.205 0.946 48.809 103.001 
IV week 0.839 0.776 39.285 68.640 
10 OP 1.25 
Baseline 1.910 1.151 76.190 163.620 
II week 1.848 1.125 75.000 153.802 
IV week 1.732 1.044 73.809 147.841 
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Patient Group 
GI of tooth 
with greatest 
inflammation 
Period Pll 
scores 
GI  
scores 
BOP 
scores 
GCF 
PGE2 
levels 
(pg/mL) 
11 CHX 1.5 
Baseline 1.741 1.352 83.333 257.581  
II week 1.428 1.153 67.857 183.963 
IV week 1.017 0.954 52.381 128.163 
12 PL 2 
Baseline 2.017 1.955 67.857 144.180 
II week 2.026 1.973 67.857 147.843 
IV week 2.098 2.000 70.238 161.282 
13 OP 2.5 
Baseline 1.562 2.303 90.476 254.002 
II week 1.526 2.196 86.904 235.210 
IV week 1.473 2.098 83.333 227.448 
14 CHX 2.5 
Baseline 2.116 2.285 96.428 360.009 
II week 1.785 1.946 79.761 262.801 
IV week 1.455 1.607 63.095 180.600 
15 PL 2.5 
Baseline 2.267 2.053 79.761 198.009 
II week 2.276 2.071 80.952 203.047 
IV week 2.330 2.142 84.523 217.811 
16 OP 2.5 
Baseline 2.375 2.187 89.285 273.060 
II week 2.304 2.089 86.904 252.945 
IV week 2.232 1.982 84.523 245.754 
17 CHX 2.25 
Baseline 2.017 1.276 91.666 176.003 
II week 1.723 1.098 75.000 125.006 
IV week 1.437 0.901 57.142 87.481 
18 PL 1.5 
Baseline 1.017 1.205 59.523 96.720 
II week 1.035 1.205 60.714 96.720 
IV week 1.044 1.276 63.095 104.641 
19 OP 1.5 
Baseline 1.285 1.196 57.142 84.241 
II week 1.241 1.125 55.952 78.343 
IV week 1.196 1.089 53.571 74.763 
20 CHX 2.5 
Baseline 2.446 1.821 78.571 163.620 
II week 2.044 1.482 65.476 119.882 
IV week 1.642 1.151 51.190 84.241 
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patient Group 
GI of tooth 
with greatest 
inflammation 
Period Pll 
scores 
GI  
scores 
BOP 
scores 
GCF 
PGE2 
levels 
(pg/mL) 
 
21 PL 2.25 
Baseline 2.437 2.107 69.047 150.971 
II week 2.446 2.107 70.238 153.182 
IV week 2.571 2.214 71.428 171.008 
22 OP 1.75 
Baseline 2.017 1.357 63.095 101.002 
II week 1.964 1.285 60.714 94.997 
IV week 1.901 1.232 57.142 90.299 
23 CHX 2.5 
Baseline 2.394 2.116 63.095 115.002 
II week 2.035 1.776 51.190 87.482 
IV week 1.687 1.419 39.285 59.283 
24 PL 2 
Baseline 2.107 1.723 71.428 168.000 
II week 2.071 1.678 70.238 165.611 
IV week 2.080 1.687 69.047 163.623 
25 OP 2 
Baseline 2.258 1.732 67.857 131.222 
II week 2.160 1.687 65.476 123.541 
IV week 2.062 1.571 63.095 117.007 
26 CHX 1.5 
Baseline 1.160 1.250 73.809 144.182 
II week 0.937 1.063 63.095 108.244 
IV week 0.687 0.812 51.190 76.003 
27 PL 2.25 
Baseline 1.651 2.035 73.809 180.600 
II week 1.642 2.026 73.809 178.510 
IV week 1.642 2.017 75.000 186.481 
28 OP 2 
Baseline 2.267 1.642 64.285 119.882 
II week 2.205 1.589 63.095 114.661 
IV week 2.187 1.491 61.904 106.693 
29 CHX 2 
Baseline 1.267 1.544 80.950 200.002 
II week 1.017 1.035 67.857 147.841 
IV week 0.696 0.991 48.809 108.242 
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Graph. 2. Changes in PlI scores post-intervention 
 
 
 
Graph. 3. Changes in GI scores post-intervention 
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Graph. 4. Percentage reduction in BOP post-intervention 
 
Graph. 5. Changes in GCF PGE2 levels post-intervention 
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Tab. 8. Comparison of CHX and OP (P value) 
(Independent samples ‘t’ test - P<0.05 was considered as statistically significant) 
 
 
Parameters Scores t-test for Equality of 
Means 
P value Comparison  
Reduction (Baseline to II week)  PlI  0.000 
GI  0.000 
BOP 0.000 
GCF PGE2  0.000 
Reduction (Baseline to IV week) PlI  0.000 
GI  0.000 
BOP  0.000 
GCF PGE2 0.000 
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The aim of this study was to compare the efficacy of conventional 
mouthrinsing (CHX) with OP (Arimedadi Taila) in preventing plaque formation and 
reducing gingival inflammation. The changes in gingival inflammation were assessed 
using conventional clinical indices. The impact of these mouthrinses on crevicular 
PGE2 levels during the interventional period (II week and IV week), was also assessed 
using ELISA technique.     
 CHX considered as the “Gold standard” mouthwash was used as the positive 
functional control in this study to assess and compare the effect of OP therapy in 
preventing plaque formation and reducing gingival inflammation. Axelsson and 
Lindhe (1987),106 have shown that CHX mouthwash is effective in the reduction of 
plaque and gingivitis. Menendez (2005),107 have shown that CHX is very effective 
against the formation of dental plaque. Many studies,5,68,75,76,78 have been reported that 
CHX resulted in greater or equal reduction in PlI and GI scores compared to OP, but 
CHX has some disadvantages like tooth staining,46,47,48,50,108 altered taste sensation46 
and allergic reactions.46,55 
 OP has been used extensively as a traditional Indian folk remedy for many 
years to prevent decay, oral malodor, bleeding gums, dryness of the throat, cracked 
lips and for strengthening teeth and gums.63 It has the following advantages over 
CHX: no staining, no allergy, more cost effective, except for the extended duration of 
rinsing with the mouthwash. 
 Any oil like sesame oil, coconut oil, sunflower oil, groundnut oil, mustard oil 
or olive oil can be used for OP procedure. There were no published data available 
comparing the efficacy of different oils, which can be used for OP. OP with 
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Arimedadi Taila has been mentioned in the ancient ayurvedic literature, as a measure 
to prevent and cure numerous oral and systemic diseases. It is indicated in almost all 
diseases of oral cavity including stomatitis, glossitis, apthous ulcers, dental caries, 
pyorrhea, gingivitis, stains removal and hyperemia of gums.6 
 Till date, there were no published data available comparing the efficacy of 
Arimedadi Taila OP with CHX mouthrinsing in preventing plaque formation, 
reducing gingival inflammation and its biomarker in GCF. The role of PGE2 as a 
biochemical marker of changes in gingival inflammation appears to have been less 
explored. Hence, this study was undertaken to compare the efficacy of Arimedadi 
Taila OP with CHX mouthrinsing in reducing plaque induced gingivitis and to assess 
the crevicular changes in PGE2 level. 
 This study was a triple blind controlled clinical trial, wherein the participants, 
investigator and statistician were unaware of the intervention being administered. 
Patients attending the dental outpatient section at Department of Periodontics, at Sri 
Ramakrishna Dental College and Hospital, Coimbatore, who were diagnosed with 
gingivitis and who had satisfied the inclusion and exclusion criteria were included in 
the study.  
 In this study, 29 gingivitis patients were randomly allocated to any of the three 
interventional groups, which involved the use of CHX (positive functional control) or 
Arimedadi OP (Test) or PL mouthrinse containing mint flavored distilled water 
(negative control) for a period of 30 days. Along with their routine oral hygiene 
measures, these patients were instructed to use the mouthrinses assigned for them 
(without disclosing its nature), as prescribed by the manufacturer, twice daily. The 
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principles of randomization and allocation concealment were followed in order to 
avoid bias. 
 In gingivitis patients, the tooth site showing greatest gingival inflammation 
and having greatest GI scores was used for GCF collection. PlI, GI, BOP scores were 
recorded at baseline, II week, IV week. Crevicular PGE2 levels were analyzed using 
ELISA. The baseline sample characteristics, Baseline, post-intervention clinical 
parameters and PGE2 levels and comparison of baseline and post-intervention findings 
have been summarized in Tab. 5, Tab. 6 and Tab. 7. respectively. 
  There was a significant decrease in PlI scores (Tab. 5, Fig. 15), following the 
use of CHX mouthrinses and OP for a period of 30 days. The mean reduction in PlI 
scores obtained with CHX mouthrinse was 16.79% at II week, 35.67% at IV week, 
22.69% between II and IV week. This reduction in PlI scores was similar, when 
compared to that obtained by Sikka et al (2011),109 who observed 16.49% and 
32.17% reduction at II week and IV week. But this reduction was lesser, when 
compared to reduction of 20.71% and 44.97% at II week and IV week respectively, as 
reported by Priya et al (2016).110 
  The mean reduction in PlI scores obtained with OP at II week (3.07%), IV 
week (6.11%) and between II and IV week (3.13%) were significantly lesser, when 
compared with CHX mouthrinsing. It was lesser, when compared to 12.71% reduction 
at IV week, as reported by Amit et al (2000)62, using sunflower OP and 13.13% 
reduction at VI week, as reported by Saravanan et al (2013),111  using sesame OP on 
plaque induced gingivitis. Overall, from baseline to II week and IV week, when the 
reduction in PlI scores were compared for the CHX and OP groups, the difference 
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was statistically significant (P=0). (Tab. 6.) CHX has anti-plaque activity which was 
found to be greater than OP and this could be attributed to the property of 
substantivity, which is the ability of an antimicrobial agent to persist within the oral 
cavity for long time. There exists no scientific explanation for anti-plaque action of 
Arimedadi Taila and whether the reduction in plaque scores observed with OP is 
purely due to physical action of an oily substance on tooth surface or by virtue of a 
biochemical action of its contents on periodontal microbiota, is yet to be ascertained.  
 In this context, it has been shown that saponification and emulsification could 
be the probable mechanisms through which sesame oil may exert its antibacterial and 
anti-plaque activity during OP.63 Hence, similar studies need to be conducted to verify 
the physical and/or biochemical processes involved in the use of Arimedadi Taila.              
 In the present study, the difference between the mean GI scores (Tab. 5, Fig. 
14) before and after CHX rinsing and OP was statistically significant. The mean 
reduction observed in GI scores following CHX rinses at II week, IV week and 
between II and IV week was 19.19%, 31.26%, and 14.94% respectively. This 
reduction in GI scores was slightly greater, when compared to that obtained by Sikka 
et al (2011)109, who observed 11.61% and 24.18% reduction in GI scores, at II week 
and IV week respectively. But this reduction was lesser when compared to 28.08% 
and 46.06% reduction at II week and IV week, respectively as reported by Priya et al 
(2016) 110. 
 In the OP group, this reduction at II week (3.67%), IV week (9.03%) and 
between II and IV week (5.56%) were significantly lesser when compared to CHX 
rinsing. It was lesser, when compared to reduction of 18.05% at II week and 33.33% 
at IV week as reported by Amit et al (2007)62, using sunflower OP and 19.84% at IV 
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week as reported by Saravanan et al (2013)111  using sesame OP on plaque induced 
gingivitis. Overall, from baseline to II week and IV week, when the reduction in GI 
scores were compared for the CHX and OP groups, the difference was statistically 
significant (P=0). (Tab. 6.)  
 Significant reduction was observed in the number of gingival sites, which bled 
on probing (Tab. 5, Fig. 16) in both CHX and OP group. However, the reduction 
observed in CHX group at II week, IV week and between II and IV week was 
16.69%, 34.59%, 21.48% respectively, as opposed to a reduction of 2.89%, 5.94% 
and 3.13% for the same, in the OP group. This reduction in BOP scores, observed in 
CHX group in our study was lesser, when compared to the reduction of 47.38%, as 
reported by Biswas et al (2014)112 at IV week.  Overall, from baseline to II week and 
IV week, when the reduction in BOP scores were compared for the CHX and OP 
groups, the difference was statistically significant (P=0). (Tab. 6.) 
 The results of this study also revealed that the use of CHX resulted in 
relatively greater reduction of crevicular PGE2 levels at II week (26.81%), IV week 
(48.68%) and between II and IV week (29.87%), as compared to lesser reduction at II 
week (6.29%), IV week (11.10%) and between II and IV week (5.14%) in OP (Tab. 5, 
Fig. 17). Overall, from baseline to II week and IV week, when the reduction in GCF 
PGE2 levels were compared for the CHX and OP groups, the difference was 
statistically significant (P=0). (Tab. 6.) To our knowledge, there were no published 
data available to compare the reduction in PGE2 levels after mouthrinsing.  
 In the PL rinsing group, because of the continued plaque accumulation, the 
patients demonstrated increased PlI, GI and BOP scores (Tab. 5). At II week, there 
was an increase of 0.1% in PlI scores, 0.15% in GI scores, 0.72% in bleeding scores 
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and 1.11% in PGE2 levels, which were not significant. At IV week, there was 
significant increase of 2.39% in PlI scores, 3.12% in GI scores, 4.11% in BOP scores 
and 8.98% in crevicular PGE2 levels.  
 These results revealed that there was an abrupt rise in crevicular PGE2 levels 
at IV week, when compared to II week. These results are in accordance with 
Heasman et al (1993)93 study on experimental gingivitis, where crevicular fluid PGE2 
levels remained fairly stable at baseline PGE2 levels for the first 3 weeks, then rose 
sharply by 2.5 fold at 4 weeks. It may not be meaningful to directly compare the 
numerical data from other studies, due to the different populations and the different 
analytical techniques employed to measure crevicular PGE2 concentrations, but trends 
can certainly be evaluated.   
 No serious adverse effects to any hard and soft tissues of the oral cavity were 
noticed, during this study. No patients reported of any mucosal changes, burning 
sensation in the oral cavity or the presence of ulcers or vesicles, which were 
suggestive of any allergic or hypersensitivity reactions. One patient of CHX group 
complained of altered taste sensation. Brownish staining was observed on the tooth 
surfaces of six patients of CHX group, while no staining reactions were observed in 
the participants of OP group. Five participants of OP group complained of abnormal 
taste sensation, associated with the use of Arimedadi Taila, which made it difficult for 
them to hold it in the oral cavity for a long time.  
 The results of the present study show that OP with Arimedadi Taila is not as 
effective as CHX in preventing plaque formation and resolving the clinical signs of 
gingival inflammation. There appears to be high inter-individual variability in 
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crevicular PGE2 levels. PGE2 levels in GCF are found to be more sensitive to changes 
in gingival inflammation. Further longitudinal studies are required to assess the 
potential of PGE2 as a marker to detect changes in gingival inflammation. 
 Limitations of our study are as follows: Microbiological assessment along 
with biochemical analysis, if considered, will add more validity to such studies. For 
better analysis of crevicular PGE2 levels, more sensitive biochemical analytic method 
like chemiluminescent assay could have been performed, rather than ELISA. 
Longitudinal studies involving larger sample size are required for better assessment of 
changes in the clinical signs and crevicular PGE2.   
The following conclusions were drawn from this study –  
 The anti-plaque and anti-gingivitis activity of CHX was superior to Arimedadi 
Taila, though there was significant reduction observed in both groups. 
 Overall, from baseline to II week and IV week, when the reduction in PlI, GI, 
BOP scores were compared for the CHX and OP groups, the difference was 
statistically significant (P=0). (Tab. 6.) 
 Following mouthrinsing, the crevicular PGE2 levels were found to be 
decreased and this reduction was greater in CHX than OP group.  
 In the PL group there was no anti-plaque and anti-gingivitis activity, which 
was in contrast to CHX and OP group.  
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 OP with Arimedadi Taila has been mentioned in the ancient ayurvedic 
literature as a measure to prevent and cure numerous oral and systemic diseases. The 
present study was done to evaluate the anti-plaque and anti-gingivitis effects of OP 
with Arimedadi Taila as compared to mouthrinsing with Chlorhexidine in gingivitis 
patients. In this study, twenty nine gingivitis patients were randomly allocated to three 
chemical plaque interventional groups which involved the use of Chlorhexidine 
(positive functional control), Arimedadi Taila (Test) and PL containing Mint flavored 
distilled water (negative control) for a period of 30 days. Along with their routine oral 
hygiene measures, these patients were instructed to use the mouthrinses assigned for 
them, as prescribed twice daily.  
The clinical parameters that were used for comparative assessment included 
Gingival and Plaque Index scores, and the number of sites with gingival bleeding 
before and after intervention at II week and IV week. The impact of these mouthrinses 
on GCF PGE2 levels during the interventional period was also assessed using ELISA 
technique.  
The following conclusions were drawn from this study –  
• The anti-plaque and anti-gingivitis activity of CHX was superior to Arimedadi 
Taila, though there was significant reduction observed in both groups. 
• Overall, from baseline to II week and IV week, when the reduction in PlI, GI, 
BOP and GCF PGE2 values were compared for the CHX and OP groups, the 
difference was statistically significant (P=0).  
• Following mouthrinsing, the crevicular PGE2 levels were found to be 
decreased and this reduction was greater in CHX than OP group.    
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• In the PL group there was no anti-plaque and anti-gingivitis activity, which 
was in contrast to CHX and OP group.   
             A household remedy like OP which saves time and money and enhances oral 
and general health needs much more exploration. Extensive studies with larger 
samples, varying time periods and long follow up times should be carried out to 
establish the efficacy of OP therapy in prevention of plaque induced gingivitis 
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